We are happy to introduce the SES Partnerships team, headed by Partnerships Director Ken Zangina. The team, comprising Ken, Emma Williams, Geoff Jones, and Dr Poh Pang, forge relationships with new and existing industry stakeholders to ensure the sustainability of our IME platforms and patient programs. The team are always on the search for new connections and contacts to grow the global footprint of our medical education and patient awareness platforms.&nbsp;&nbsp;&nbsp;<h2>“Bolt On” initiatives</h2>We are pleased to have secured the first supporters for the following newly launched bespoke education initiatives. We are seeking additional grants from industry to ensure that these initiatives have credible representation across the scope of therapies.&nbsp;&nbsp;<h3>“Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis”&nbsp;</h3>This clinical trials club is a live webinar series where members of our MPN steering committee are&nbsp;joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support HCPs in understanding what the latest news means for clinical practice. They offer the ideal solution to address a key learning gap of “suboptimal knowledge of novel therapeutic targets in MPN.”&nbsp;&nbsp;<h3>“Holistic pain management in multiple myeloma”&nbsp;</h3>This accredited digital symposium provides the ideal solution to support pain management education in the care of patients with multiple myeloma. This digital event will offer learners the opportunity to learn more about patient needs, holistic pain management, and treatment considerations, and will present the most up-to-date information.&nbsp;&nbsp;Please <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank"> contact the Partnerships team</a> if you would like to learn more about supporting these education initiatives.&nbsp;<h2>MDS Right Global Guidelines</h2>Partnered with the MDS Foundation, SES is pleased to support the project management of the MDS Right Global Guidelines update. We are thankful to our latest supporter AbbVie whose support, in addition to Geron and Takeda, will allow for this critical work to progress.&nbsp;&nbsp;If you would like further information, or would like to support this project, please <a href="mailto:Geoff.Jones@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank"> contact Senior Partnership Manager Geoff Jones</a><h2>New Supporters</h2><a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank"> AML Hub</a> – Thermo fisher: We are thrilled to announce that we have our first diagnostic company supporting the AML Hub at Bronze level. We would like to thank ThermoFisher for their support of independent medical education, and we hope that this reaffirms the key role diagnostic stakeholders play in ensuring patients with AML receive the most appropriate treatment.&nbsp;&nbsp;&nbsp;&nbsp;<a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank"> Lymphoma Hub</a> – Pharmacyclics: This organization has a strong heritage in treating chronic lymphocytic leukemia and have chosen to support the Lymphoma Hub at Gold level. This significant level of funding will result in the availability of further materials on lymphoma treatment and research.&nbsp;Lupus Hub – GSK: Lupus Hub is launching in 2022, and we are excited to announce that we have our first supporter for the hub—GSK—at Platinum level. This is fantastic news, and we look forward to welcoming an accompanying supporter to ensure that this platform can be launched as a multi-supported initiative in 2022.&nbsp;&nbsp;<a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank"> MDS Hub</a> – BMS: We are pleased to confirm that BMS will be continuing their support for the MDS Hub at Bronze level. We would like to thank BMS for their steadfast support of this key platform.&nbsp;&nbsp;&nbsp;<h2>Congress summary reports</h2>The Partnership team recently shared the congress summary reports for ASH with our Gold and Platinum IME supporters. These reports include key insights related to ASH, including&nbsp;<ul><li>recommendations from the Lymphoma Hub steering committee for the top abstracts in lymphoma and CLL from ASH 2021;&nbsp;</li><li>the Top 5 communications that gained the most engagement during live congress coverage, based on the number of impressions and engagement on Twitter; and&nbsp;</li><li>tailored engagement statistics from the Lymphoma and CLL community in relation to specific supporter content.&nbsp;&nbsp;</li></ul>These reports are a great way for our supporters to gain further insights into specific disease areas and how the content produced for the hubs is received by the community. If access to these reports will be of utility in the future, please speak with a member of the Partnerships team on <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank"> partnerships@scientificeducationsupport.com</a> to discuss how we can provide these reports, which would be tailored to your organization.&nbsp;&nbsp;<h2>Congress news: EBMT</h2>Senior Partnerships Managers Emma Williams and Poh-Choo Pang will be in Prague on March 19–23, 2022, for the <a href="https://www.ebmt.org/annual-meeting" rel="noopener noreferrer" target="_blank"> 48th EBMT Annual Meeting</a> . They are excited to meet with supporters and learn about the latest developments relating to hematopoietic stem cell transplantation and cellular therapy research. If you have an interest in these areas and are keen to speak more with our team, <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank"> please get in touch</a> or make contact with <a href="https://www.linkedin.com/in/emmamitchel/" rel="noopener noreferrer" target="_blank"> Emma</a> or <a href="https://www.linkedin.com/in/pcpang/" rel="noopener noreferrer" target="_blank"> Poh</a> directly on LinkedIn.

We are happy to introduce the SES Partnerships team, headed by Partnerships Director Ken Zangina.

dd75fa48673f9bf3adc2962ee5779883.png

Partnerships Update-February 2022

This year’s <a href="https://ammf.org.uk/ammf-conference-2022/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AMMF European Cholangiocarcinoma Conference</a> is being hosted as a hybrid event on May 11–13, with the face-to-face sessions taking place in Stansted in the UK. AMMF – The Cholangiocarcinoma Charity – is the not-for-profit partner for the <a href="https://globalccaalliance.com/en" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Global Cholangiocarcinoma Alliance</a> (GCA), whose founder and CEO, Helen Morement, is the co-chair, guiding the steering committee alongside co-chairs Stacie Lindsey (The Cholangiocarcinoma Foundation, US) and Professor Ross Andrews (Imperial College London and Khon Kaen University, Thailand).&nbsp;&nbsp;The 3-day event is being co-chaired by Professor Juan Valle (University of Manchester and The Christie, UK) and Professor Jesús Bañales (Biodonostia HRI, Spain), both internationally renowned specialists at the forefront of the cholangiocarcinoma (CCA) world. Professor Bañales is a member of the highly experienced and dedicated global steering committee for the GCA, who meet regularly to steer and guide the initiative. It includes representatives from the following CCA communities: patient advocacy, professional societies, leading physicians, and researchers.&nbsp;The co-chairs of the conference will be joined by speakers from around the world to discuss the advances made and challenges faced in the understanding of CCA, globally. The conference welcomes a varied audience, including patients and carers, clinical nurse specialists (UK), healthcare professionals, advocates, and industry from around the world, and the conference program reflects this. Among the wide variety of topics, there will be sessions on molecular profiling, the AMMF CCA data project, surgery and transplantation, pathology, a patient perspective, and views from around the world, including France, the Netherlands and Thailand. A full conference program can be viewed <a href="https://ammf.org.uk/wp-content/uploads/2022/04/AMMF-Conference-Programme-2022-A4-18.4.22.pdf" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">here</a>.&nbsp;Featured in the conference program are GCA co-chair, Professor Ross Andrews, who will be hosting the Professor Puangrat Yongvanit Memorial Lecture, and other steering committee members, including Professor Shahid Khan (Imperial College London, UK), Professor Vincenzo Cardinale (Sapienza University, Italy), Professor Narong Khuntikeo (Khon Kaen University, Thailand), and Dr Shijie Cai (University of Oxford, UK).&nbsp;SES will be attending the conference on behalf of the GCA and will be available for meetings and questions throughout the 3-day event. The GCA will be hosting a closed steering committee meeting on Thursday, May 12, 2022. Following the session, there will be a short Q&amp;A session at 19:00 BST, offering an opportunity to join virtually or in person, speak with the steering committee members and the GCA secretariat, and to gain further information about strategy and activities for 2022/23. For more information about the session or the alliance, or to organize a meeting, please email us on <a href="mailto:SESGCA@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">SESGCA@scientificeducationsupport.com</a>.&nbsp;&nbsp;If you are interested in finding out more about the GCA’s activities in 2022/23 and packages for support, please get in touch as we would be interested in organizing a call to discuss further.&nbsp;&nbsp;

The GCA will attend the AMMF’s Hybrid 2022 European Cholangiocarcinoma Conference 

April newsletter images 0.1_GCA-AMMF_web.png

AMMF’s Hybrid 2022 European Cholangiocarcinoma Conference 

IME stands for independent medical education—but what exactly is IME, what are the rules that surround it, and why is it a valuable addition to your medical education strategy? This article will take you through the answers to these questions. If you have any additional questions, please don’t hesitate to get in touch.<h3>What is IME?</h3>IME is education that is produced without any involvement or influence from the pharmaceutical company providing funding for the project. Once the company has agreed to support the education, the project operates at an arm’s length, and the IME agency running the project along with the faculty have the final decisions. You may also have heard of CME; this stands for continued medical education. CME follows the same rules and best practice standards as IME, but an accredited version. CME projects undergo review from accrediting bodies and, provided they are approved, any healthcare professional who completes a CME-accredited education module can claim a credit towards their professional development. Many countries require healthcare professionals to gain a certain amount of CME credits across a time period to maintain their licences.<h3>Why may financially supporting IME be a useful addition to your strategy?</h3><ol><li>Some healthcare professionals are sceptical of company-driven education as they believe it will be biased towards the company’s product. By investing in IME on top of your company-driven education projects, you will be able to reach a wider audience. In fact, healthcare professionals prefer IME/CME to other sources of information, including journal articles and publications. (1,2)</li><li>In IME, we are allowed to discuss the impact of clinical trial data on the future of clinical practice. This ensures that, when a new therapy is launched, healthcare professionals have the knowledge needed to swiftly integrate this into their practice. In company-driven education, this type of discussion needs to wait until after launch.</li><li>One of the rules of IME (described further below) is the prohibition of company review of the content via Veeva or equivalent. This means IME is a lot less work for your internal team. If you are stretched resource wise but have leftover budget, IME could be a great solution for you.</li><li>By supporting IME initiatives, you are raising your profile among healthcare professionals as a company committed to the development of knowledge in the field, positive clinical practice change in the field and, ultimately, improving patient care.</li><li>At SES, we will provide you with insights in return for your support. This includes robust needs assessments highlighting the challenges faced by our target healthcare professional audience and outcomes, to show how the education you have supported has helped to solve these challenges. This provides you with valuable insights you can use to develop your medical and commercial strategies further and, importantly, prove the value of your investment in IME to key stakeholders in your team.</li></ol><h3>What are the rules of IME?</h3><ol><li>All content for IME projects should be developed at arm’s length, with no involvement or review by the financial supporter. Veeva reviews or equivalent are not allowed for IME projects.</li><li>IME projects should be faculty led, with the faculty and education company working together to direct the content. The supporter should not have any influence on faculty selection.</li><li>IME projects should be non-commercial. This means they should not mention any brand names, incorporate any of the supporter’s strategic messaging, or have any company branding. At SES, we have a strict firewall in place that prevents communication between teams working on commercial and independent projects, and there is no crossover of team members. This ensures our teams have no commercial knowledge of supporters’ strategies when working on IME projects and do not insert any bias into content.</li><li>This brings us on to the fourth rule: IME projects should be fair and balanced and not represent any bias towards one company’s product over another. All relevant therapeutics must be discussed alongside one another, and all information must be supported by clear scientific evidence. This allows healthcare professionals to make informed and independent clinical care decisions. It may be that one product does appear favourable over the others, but as long as the rule of fair and balanced representation in accordance with the evidence base has been followed, then this is allowed. At SES, we have an experienced team who have been running IME projects for over 10 years.</li></ol>There are multiple ways you can partner with us and support our hubs and patient programs: ​<ul><li>Become a supporter of our hub standard offerings</li><li>Support our hub ​bolt-on projects</li><li>Send us your proposal request and let us share our bespoke ideas</li></ul>Please don’t hesitate to <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank"> get in touch</a> if, having read this article, you would like to hear more about IME.References1. Policy and medicine. Global Education Group survey: 98% credit CME as helpful in improving patient care. http://www.policymed.com/2013/04/global-education-group-survey-98-credit-cme-as-helpful-in-improving-patient-care.html. Published May 6, 2018. Accessed Feb 10 , 2022.2. EPG Health Media. Continuing medical education (CME): the behaviour, demands and views of healthcare professionals (HCPs) in Europe. https://www.epghealthmedia.com/asset/6E422815-2D8C-473C-A9B86AB04E8C5E3D/. Published Nov 2012. Accessed Feb 10, 2022).

IME stands for independent medical education—but what exactly is IME, what are the rules that surround it, and why is it a valuable addition to your medical education strategy?

a75bdfd42dfa0e7ff577fadfc9a46b13.png

What is IME? The values and the rules for the pharmaceutical industry 

The Partnerships team recently attended <a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank">the 48th Annual Meeting of the EBMT</a>. We fully support the decision taken by the event organisers to move the event to a remote setting to assist the refugee situation in Ukraine. The team found the virtual sessions to be very insightful and informative. Some of the sessions attended by the team within the industry symposia component included:&nbsp;&nbsp;&nbsp;<ul><li>“What’s new in GvHD in 2022: Tackling the unmet needs from prophylaxis to treatment” (sponsored by Sanofi)&nbsp;</li><li>“Extracorporeal photopheresis: Immunomodulatory therapies and their use in GvHD” (sponsored by Mallinckrodt)&nbsp;</li><li>“Recent advancements in immune therapies for multiple myeloma” (sponsored by Bristol Myers Squibb)&nbsp;</li><li>“Looking deep into the complexities of multiple myeloma: How to decide treatment and measure outcomes” (sponsored by Pfizer)&nbsp;</li><li>“Cell therapy: Revolutionary ideas improving today’s practices” (sponsored by Miltenyi Biomedicine )&nbsp;</li><li>“Will transplant continue to be the SoC in R/R DLBCL” (sponsored by Gilead–Kite)&nbsp;</li></ul><h2>New supporter update&nbsp;</h2>The <a href="https://rareanaemias.org/" rel="noopener noreferrer" target="_blank">Rare Anaemias International Network</a> (RAIN): RAIN is a global community-based ecosystem made of patient advocacy associations and individuals supporting rare anemias. We are delighted to welcome Immunovant as our second founding supporter of the network. The support provided from our industry supporters is key in helping RAIN achieve its mission to improve the health and quality of life of people with rare anemias.&nbsp;<a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank">MDS Hub</a> and <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank">AML Hub</a>: We are delighted to confirm that Janssen will be continuing their support of the <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank">AML Hub</a>, and we are thrilled to welcome them as a new supporter of the <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank">MDS Hub</a>. As Bronze level supporters, Janssen’s support of this platform, along with industry partners, is critical in achieving our vision that every treatment team and researcher can have instant access to expert opinions and the latest evidence-based information on AML and MDS.&nbsp;<a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank">AML Hub</a>: AbbVie has kindly reconfirmed its support of the AML Hub in 2022. We are pleased to have this important industry stakeholder continue to support the platform at Silver level. This year will be significant for innovative therapies across hematology, and we appreciate the support provided to assist our users in understanding the best practice use of novel agents in AML.&nbsp;<h3>Bespoke educational opportunities&nbsp;</h3>We are seeking grants from our existing and new industry partners to ensure that the following newly created bespoke educational initiatives have credible representation across the scope of therapies.&nbsp;“How to select and sequence treatments for steroid-refractory GvHD”&nbsp;This interactive case study educational project will offer healthcare professional (HCP) users the potential to transition from simple knowledge gains to changes in patient care outcomes in the management of this disease. Learners will be presented with a patient case, identified challenge, or specific decision, along with supporting data. The learner will be guided/coached by a leading expert based on their treatment decision and provided with the recommended options available. After engaging with this content, we hope that users will be able to explain the role of new agents in the GvHD therapeutic landscape, including optimal patient selection and sequencing.&nbsp;“Towards personalized therapy in relapsed multiple myeloma”&nbsp;This digital symposium will help users describe novel therapeutic targets in multiple myeloma and explain the mechanisms of action for new agents in the disease space. HCP users will also be able to&nbsp;&nbsp;state the rationale for selecting treatments in relapsed/refractory disease based on disease- and patient-related factors. The symposium will be designed in collaboration with the experienced and world-renowned <a href="https://multiplemyelomahub.com/steering-committees/steering-committee" rel="noopener noreferrer" target="_blank">Multiple Myeloma Hub Steering Committee</a>, to ensure relevance and accuracy in addition to attracting a big audience.&nbsp;“Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis”&nbsp;The clinical trials club is a live webinar series where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support HCPs in understanding what the latest news means for clinical practice. They offer the ideal solution to address a key learning gap of “Suboptimal knowledge of novel therapeutic targets in MPN.”&nbsp;“Holistic pain management in multiple myeloma”&nbsp;This accredited digital symposium would offer the ideal solution to support pain management education in the care of patients with multiple myeloma. This digital event will offer learners the opportunity to learn more about patient needs, holistic pain management, and treatment considerations, and will present the most up-to-date information.&nbsp;Please <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">contact the Partnerships team</a> on if you would like to learn more about supporting these educational initiatives.&nbsp;

The latest update from the Partnerships Team at Scientific Education Support.

partnerships update.png

Partnerships update-March 2022

One of the main goals of our education hubs is to provide up-to-date information on the different medical fields that we cover. Thus, a lot of the content that can be found on our websites summarizes and discusses the data presented in key medical conferences happening across the globe.&nbsp;Every year, the SES team prepares a comprehensive congress coverage plan tailored for each hub, including live coverage on the hub social media channels, expert interviews, and written summaries of the most relevant oral presentations. This plan is reviewed biannually by the corresponding steering committee. Once the conference program is available, Indication Leads conduct a thorough review to select the essential sessions to cover live and/or as enduring content. These sessions consider the unmet educational needs of focus for each hub and any additional themes suggested by our supporters and approved by our steering committee members.&nbsp;During the last couple of years, there has been a major breakthrough in medical education that will probably have a long-lasting impact on our understanding and expectations of medical conferences. Due to the pandemic, the necessary virtual format of such events was possible thanks to massive efforts and resources from the organizing medical societies, as well as the pharmaceutical industry. We have seen not only a growing number of events being organized but also record numbers of attendees and abstracts being presented. In 2021, our hematology hubs reported on disease and drug development updates from more than 30 conferences.&nbsp;Although there was an initial reluctance towards virtual congress attendance, the opportunities that it brought rapidly exceeded the downsides. The reduction in registration and travel costs improved access to these events globally while also facilitating the attendance of a conference without missing work or family duties. Virtual formats adapt easily to user preferences and interests and allow new opportunities for patient inclusion, with patients attending and presenting their experiences with the disease and treatment. Altogether, after 2 years and despite a steep learning curve, a recent survey of more than 1,000 doctors from 75 countries found that 58% of physicians preferred virtual and hybrid conferences moving forward.&nbsp;The current environment, eager to innovate, has also led to an ongoing discussion on improving the learning experience during attendance of a medical conference. The model of a 10-minute talk followed by a 5-minute Q&amp;A, with barely any time for discussions with the presenting author, is no longer the gold standard. Instead, new approaches focus on extended panel discussions and live, open chats to maximize engagement and facilitate networking opportunities.&nbsp;<h2>SES Vision for medical education coverage</h2>At SES, we share this vision of a more accessible and interactive medical education, and we believe that social media is fundamental to achieving this goal. During live congress coverage on our multiple Twitter accounts, we provide key data presented from the most awaited trials and drugs, and promote further discussion through questions and polls directed at our audience. We also involve the presenting authors and encourage them to join the conversation through social media or video interviews, where we allow them to expand on their work and give new perspectives on the data presented and their relevance in clinical practice and patient outcomes.&nbsp;The purpose of our SES education hubs is to go beyond the medical conference and provide an enhanced learning experience, where the user can be part of the conversation. Our audience are able to quickly grasp live highlights from the most important congresses in their field and come back weeks later at their own pace to delve into the details of educational and oral abstract sessions in our enduring hub content.&nbsp;In these exciting times for medical education, we encourage you to follow the SES and hub social channels, and check out our Hub Twitter Moments during the latest conference covered live: <a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank">the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation!&nbsp;</a>Resources&nbsp;<a href="https://pharmaphorum.com/sales-marketing/disrupted-medical-conferences-part-1-the-new-normal-is-already-here-get-used-to-it/" rel="noopener noreferrer" target="_blank" style="color: inherit;">Pharmaphorum. Disrupted medical conferences: Lessons learnt.</a><a href="https://pharmaphorum.com/sales-marketing/disrupted-medical-conferences-part-1-the-new-normal-is-already-here-get-used-to-it/" rel="noopener noreferrer" target="_blank" style="color: windowtext;"> </a><a href="https://pharmaphorum.com/sales-marketing/disrupted-medical-conferences-part-1-the-new-normal-is-already-here-get-used-to-it/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">https://pharmaphorum.com/sales-marketing/disrupted-medical-conferences-part-1-the-new-normal-is-already-here-get-used-to-it/</a>. Published March 15, 2022. Accessed March 22 2022.&nbsp;G-Med. Medical Conference Highlights. <a href="https://www.g-med.info/_files/ugd/2e94f6_b4a5efd7f0044f61bee7a3d5b8733b26.pdf" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">https://www.g-med.info/_files/ugd/2e94f6_b4a5efd7f0044f61bee7a3d5b8733b26.pdf</a>. Published January 2022. Accessed March 22, 2022.&nbsp;

An introduction to the coverage that Scientific Education Support provide for medical education conferences.

congress coverage.jpeg

SES and medical conferences: How to keep the conversation going 

An overview of the case studies that SES can provide that support unmet medical education needs.

Interactive case studies.jpeg

Introducing our interactive case studies

We are pleased to announce the launch of <a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know ALL</a>, a global education and awareness initiative that focuses solely on acute lymphoblastic leukemia (ALL), with the aim to provide patients and caregivers with information, resources, and support to deal with ALL. Know ALL is guided by a highly experienced global ambassador group who meet regularly to ensure the voice of patients and their families is at the core of the initiative.&nbsp;Founded in 2022, Know ALL is a collaboration between <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support (SES)</a> and the <a href="https://acuteleuk.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Acute Leukemia Advocates Network (ALAN).</a> ALAN is a global network of patient advocates who are collaborating with SES on Know ALL to ensure that the ALL community has access to the latest information and resources, providing the best possible support and care for patients with ALL and their families.&nbsp;SES and ALAN would like to acknowledge support, through independent grants, from Amgen and Jazz Pharmaceuticals, without whom the launch of this initiative would not have been possible.&nbsp;With the mission to drive awareness of ALL globally, we are seeking further industry support through independent grants for Know ALL to deliver upon a number of key objectives, particularly the sharing and exchanges of medical advances in ALL. Among the priority educational gaps identified by the ambassador group is the need for education on treatment, including emerging therapies, age related protocols, and other considerations linked to treatment.&nbsp;By funding Know ALL, we believe that industry can help support the educational needs of the ALL community as well as receive valuable insights into the patient experience. We would be delighted to welcome interested industry parties to support the initiative.&nbsp;&nbsp;“Know ALL is important because all cancers should have individual representation. The Know ALL initiative will provide the space for both current, past, and future patients with ALL to access high-quality information about their cancer, both from each other and from experts. I’m proud of Know ALL because it provides visibility for a not often spoken about cancer, and it is something using the voices of the people ALL affects to build resources that patients with ALL will find useful.” Jaymz Goodman, a patient in remission from ALL and a Know ALL ambassador.&nbsp;Please <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">contact the partnerships team</a> for more information on how to support this initiative.&nbsp;For more information on Know ALL, please visit <a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">know-alleukemia.com</a> or contact <a href="mailto:ses_knowall@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ses_knowall@scientificeducationsupport.com</a>.&nbsp;Connect with our social channels:&nbsp;Twitter: <a href="https://twitter.com/_KNOW_ALL" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">@_KNOW_ALL</a>&nbsp;Facebook: <a href="https://www.facebook.com/Know-ALL-102633885259544" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know ALL</a>&nbsp;LinkedIn: <a href="https://www.linkedin.com/company/76743323/admin/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know ALL</a>&nbsp;Instagram: <a href="https://www.instagram.com/know.all2021/?hl=en" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">know.all2021</a>&nbsp;&nbsp;

Announcing the launch of Know ALL, a global education and awareness initiative that focuses solely on acute lymphoblastic leukemia (ALL), with the aim to provide patients and caregivers with information, resources, and support to deal with ALL

Know ALL SES launch.png

Know ALL, a new global community in acute lymphoblastic leukemia, has launched! 

The <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, run by <a href="https://www.scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support (SES)</a> in partnership with the <a href="https://www.leukemia-net.org/content/home/index_eng.html" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">European LeukemiaNet (ELN)</a>, is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in graft-versus-host disease (GvHD). The GvHD Hub remains dedicated to bringing you the latest information regarding COVID-19 and its implications in patients undergoing hematopoietic stem cell transplantation, as well as addressing the unmet medical needs in the field.&nbsp;During Q1 of 2022, the GvHD Hub attended the <a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt%22%20/h%20%20HYPERLINK%20%22https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">48th Annual Meeting of the EBMT</a>, which was held in a virtual format. For the event, we provided live coverage across multiple social media channels, including Twitter, for which a collection of all activity has been captured in a <a href="https://twitter.com/i/events/1508805396416319497" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">Twitter Moment</a>. Our main areas of interest included the treatment of chronic GvHD, managing the multiple facets of GvHD treatment, and the tools available for risk stratification of GvHD. The social coverage for the congress helped generate over 39,000 impressions on our social channels and contributed towards over 3,400 website users during the quarter. The metrics seen during Q1 demonstrate the impact the hub has in the GvHD community; therefore, we will continue to provide our audience with the latest updates and insights in GvHD. During Q1, we also published a <a href="https://gvhdhub.com/medical-information/considerations-in-the-treatment-of-agvhd" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">visual abstract</a> that represents considerations in the treatment of acute GvHD.&nbsp;Reviewing the GvHD Hub’s impact this quarter, Sam Larkin, GvHD Hub’s Content Lead at Scientific Education Support, said:&nbsp;“During this quarter, the GvHD Hub provided live session coverage for the 48th Annual Meeting of the EBMT, maintaining an online presence to facilitate the dissemination of key updates and breakthroughs in GvHD worldwide.&nbsp;&nbsp;“As part of our commitment to continuously enhance the hub’s user experience, we also introduced a new digital innovation with the addition of Google Translate to the hub. As a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.&nbsp;“The GvHD Hub is supported by Incyte , Novartis , Syndax , Kadmon and BMS; we remain grateful for their invaluable support. We would also like to thank the GvHD Hub Steering Committee for their continued guidance.”&nbsp;ENDS&nbsp;For more information on the GvHD Hub, please visit <a href="http://www.gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">gvhdhub.com</a>.&nbsp;For media enquiries or to explore collaboration opportunities, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a> or <a href="mailto:Barry.Connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Barry.Connolly@scientificeducationsupport.com</a>.&nbsp;NOTES TO EDITOR&nbsp;About graft-versus-host disease (GvHD)&nbsp;GvHD is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of posttransplant mortality and morbidity. It is caused by immune incompatibility between the graft (donor) and recipient tissues. The graft cells recognize the recipient tissues as foreign and mount an immune response against them.&nbsp;About the GvHD Hub&nbsp;The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education on GvHD. Our aim is to enhance knowledge of GvHD through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.&nbsp;The GvHD Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the GvHD Hub supports HCPs worldwide.&nbsp;Founded in partnership with the European LeukemiaNet in 2018, the GvHD Hub is guided by an international <a href="https://gvhdhub.com/steering-committees/steering-committees-1" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">steering committee</a> of experts in the field of GvHD. The steering committee meet regularly to discuss the performance of the GvHD Hub and to devise action plans on how best to support the GvHD community and address any unmet educational needs.&nbsp;GvHD Hub supporters&nbsp;Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.&nbsp;<ul><li>Incyte&nbsp;</li><li>Novartis&nbsp;</li><li>Syndax&nbsp;</li><li>Kadmon&nbsp;</li><li>BMS&nbsp;</li></ul>If you are interested in becoming an GvHD Hub supporter, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a>.&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;SES already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>, and <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>.&nbsp;About the European LeukemiaNet&nbsp;220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.&nbsp;

Asset 5.png

GvHD Hub Press Release Q1: The Gvhd Hub in Q1 2022: Boosting Levels Of Knowledge In The Graft-Versus-Host Disease Setting Through Key Updates And Congress Coverage

The <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, run by <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support (SES)</a> in partnership with the <a href="https://www.esh.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">European School of Haematology (ESH)</a>, is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in acute lymphoblastic leukemia (ALL). The ALL Hub has continued to promote significant developments in the treatment and research of ALL throughout the first quarter of 2022.&nbsp;In Q1 2022, the ALL Hub provided extensive coverage of three key congresses, presenting the latest advances in ALL. In February, we virtually attended the <a href="https://www.ebmt.org/events/ebmt-eha-4th-european-car-t-cell-meeting" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">4th European CAR T-cell Meeting</a>, providing live social media coverage and conducting interviews with CAR T-cell specialists. In March, we interviewed leading ALL experts at the <a href="https://www.esh.org/conference/3rd-how-to-diagnose-and-treat-acute-leukaemias/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">3rd How to Diagnose and Treat Acute Leukaemias </a>congress and in the same month, at the <a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">48th Annual Meeting of the EBMT</a><a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank" style="color: inherit;">, </a>we provided live updates from eminent speakers on the latest developments in stem cell transplantation and cellular therapy. The coverage we provided for these congresses contributed to over 14,000 impressions on our social channels and over 6,000 page views this quarter.&nbsp;The ALL Hub also released a <a href="https://lymphoblastic-hub.com/medical-information/blinatumomab-for-b-all-rialto-final-analysis" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">visual abstract</a> this quarter, representing key data from the final analysis of the RIALTO study, a multicenter expanded access program evaluating the safety and efficacy of blinatumomab in pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (B-ALL).&nbsp;Reviewing the ALL Hub’s impact this quarter, Ellen Jenner, Scientific Team Lead, SES said:&nbsp;&nbsp;“The ALL Hub’s aim is to enhance knowledge of ALL through multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management. To achieve this, we share evidence-based articles, drug and trial updates, and expert opinions. Our international congress coverage allows us to disseminate the very latest developments to clinicians and researchers around the world.&nbsp;“In Q1, the ALL Hub attended some of the leading congresses for acute lymphoblastic leukemia and provided live coverage of sessions as well as Hub content on the cutting-edge research presented by key experts in the field. By attending these events, we can provide every treatment team and researcher with instant access to expert opinions and the latest evidence-based information on ALL, which we believe will aid treatment decisions and improve the lives of patients with ALL, globally. As part of our commitment to continuously enhance our user experience, we also introduced a new digital innovation with the addition of Google Translate to the Hub. As a result, our content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.”&nbsp;Everyone at the ALL Hub would like to thank its Steering Committee for their continued support and our supporters—Novartis, Amgen, and Pfizer—without whom the platform would not be possible.&nbsp;ENDS&nbsp;For more information on the ALL Hub, please visit <a href="https://lymphoblastic-hub.com/steering-committees/steering-committee" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">lymphoblastic-hub.com</a>.&nbsp;For media enquiries or to explore collaboration opportunities, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a> or <a href="mailto:Barry.Connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Barry.Connolly@scientificeducationsupport.com</a>.&nbsp;NOTES TO EDITOR&nbsp;About acute lymphoblastic leukemia (ALL)&nbsp;ALL is a rare form of blood cancer characterized by uncontrolled proliferation of immature stem cells of lymphoid lineage. It is the most common form of leukemia in children, and the second most common acute leukemia in adults.&nbsp;ALL is associated with various chromosomal and genetic abnormalities, which has led to the development of risk stratification and promising new targeted agents. However, while treatment outcomes are favorable in childhood ALL, in older patients, poor prognosis and treatment tolerability are still a major concern.&nbsp;About the ALL Hub&nbsp;The ALL Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education on ALL. Our aim is to enhance knowledge of ALL through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.&nbsp;&nbsp;The ALL Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the ALL Hub supports HCPs worldwide.&nbsp;Founded in partnership with the European School of Haematology (ESH) in 2021, the ALL Hub is guided by an international <a href="https://lymphoblastic-hub.com/steering-committees/steering-committee" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">steering committee</a> of experts in the field of ALL. The steering committee meet regularly to discuss the performance of the ALL Hub and to devise action plans on how best to support the ALL community and address any unmet educational needs.&nbsp;ALL Hub supporters&nbsp;Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.&nbsp;<ul><li>Amgen&nbsp;</li><li>Novartis&nbsp;</li><li>Pfizer&nbsp;</li></ul>If you are interested in becoming an ALL Hub supporter, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a>.&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>, and <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>.&nbsp;&nbsp;About the European School of Haematology (ESH)&nbsp;The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical, and therapeutic research in haematology.&nbsp;

Asset 13.png

ALL Hub Press Release Q1:  ALL Hub Continues to Enhance Global Knowledge Of Acute Lymphoblastic Leukemia Through Extensive Congress Coverage

The <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, run by <a href="https://www.scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support</a> in partnership with the <a href="https://www.eli.eu/en/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">European Lymphoma Institute</a>, is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in lymphoma. The Lymphoma Hub covered three key conferences this quarter (Q1), ensuring the Lymphoma community receive the latest news and insights in Lymphoma treatment and research.&nbsp;&nbsp;In February, the Lymphoma Hub provided coverage for the <a href="https://www.ebmt.org/events/ebmt-eha-4th-european-car-t-cell-meeting" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">4th European CAR T-cell Meeting</a><a href="https://www.ebmt.org/events/ebmt-eha-4th-european-car-t-cell-meeting" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: windowtext;">, </a>providing live social media updates, interviews with leading experts, and congress related articles for our audience. The coverage focused on research areas such as the cardiotoxicity of CAR T-cell therapy and the impact of COVID-19 on delivering CAR T-cell treatment. A complete overview of our coverage is available from our <a href="https://twitter.com/i/events/1493225309621170176" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Twitter Moment</a>.&nbsp;&nbsp;In March, the Lymphoma Hub attended the <a href="https://www.esh.org/conference/2nd-translational-research-conference-chronic-lymphocytic-leukaemia/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">2nd Translational Research Conference</a>: Chronic Lymphocytic Leukemia and conducted interviews with leading CLL experts. In the same month, at the <a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">48th Annual Meeting of the EBMT</a><a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: windowtext;">, </a>we provided live updates on talks from eminent speakers and specialists on the latest developments in cellular therapy. Our live EBMT coverage is available to view on our <a href="https://twitter.com/i/events/1506600695088267270" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Twitter Moment</a>. Our social coverage for these key congresses contributed to over 200,000 impressions on our social channels and over 15,000 website users this quarter.&nbsp;This quarter, the Lymphoma Hub also released a <a href="https://lymphomahub.com/medical-information/axi-cel-vs-soc-for-rr-lbcl-zuma-7-primary-analysis" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">visual abstract</a> which presents key data from the primary analysis of the phase III ZUMA-7 study (<a href="https://clinicaltrials.gov/ct2/show/NCT03391466" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">NCT03391466</a>), evaluating the clinical efficacy of axicabtagene ciloleucel versus standard-of-care second-line therapy in adult patients with relapsed/refractory large B-cell lymphoma.&nbsp;Reviewing the Lymphoma Hub’s activity this quarter, Ellen Jenner, Scientific Team Lead, Scientific Education Support, said:&nbsp;“This quarter has been an especially busy period for the Lymphoma Hub. As part of our commitment to continuously enhance the hub’s user experience, we have introduced new digital innovations which include learning objectives and interactive quizzes to test the user’s knowledge before and after viewing our content. We have also updated the Hub with Google Translate, and as a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.&nbsp;“By attending key congresses and providing extensive coverage, we bring education to those who cannot attend and ensure that they are able to have sight of educational messages and vital updates in lymphoma and CLL.”&nbsp;Activity such as this would not be possible without our supporters. We would like to take this opportunity to show our gratitude for our existing supporters—Bristol Myers Squibb, Incyte, Roche, Pharmacyclics, BeiGene, ADC Therapeutics, Genentech, Novartis, Epizyme, Karyopharm Therapeutics, TG Therapeutics. We would also like to thank our Steering Committee for their continued guidance and support.&nbsp;ENDS&nbsp;For more information on the Lymphoma Hub, please visit <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">lymphomahub.com</a>.&nbsp;&nbsp;For media enquiries or to explore collaboration opportunities, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a> or <a href="mailto:Barry.Connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Barry.Connolly@scientificeducationsupport.com</a>.&nbsp;NOTES TO EDITOR&nbsp;About lymphoma&nbsp;Lymphoma is described as the development of neoplastic cellular growth—cancer—in the lymphatic system. Lymphomas are divided into two major categories: Hodgkin and non-Hodgkin lymphomas, where the latter is more common.&nbsp;About the Lymphoma Hub&nbsp;The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge of lymphoma and CLL through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.&nbsp;The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the Lymphoma Hub supports HCPs worldwide.&nbsp;Founded in partnership with the European Lymphoma Institute (ELI) in 2014, the Lymphoma Hub is guided by an international <a href="https://lymphomahub.com/steering-committees/executive-steering-committee" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">steering committee</a> of experts in the field of lymphoma and CLL. The steering committee meet regularly to discuss the performance of the Lymphoma Hub and to devise action plans on how best to support the lymphoma community and address any unmet educational needs.&nbsp;Lymphoma Hub supporters&nbsp;Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.&nbsp;<ul><li>Bristol Myers Squibb&nbsp;</li><li>Incyte&nbsp;</li><li>Roche&nbsp;</li><li>Genentech&nbsp;</li><li>Novartis&nbsp;</li><li>ADC Therapeutics&nbsp;</li><li>Epizyme&nbsp;</li><li>Karyopharm Therapeutics&nbsp;</li><li>TG Therapeutics&nbsp;</li><li>Pharmacyclics&nbsp;</li><li>BeiGene&nbsp;</li></ul>If you are interested in becoming a Lymphoma Hub supporter, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a>.&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>, and <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>.&nbsp;About The European Lymphoma Institute (ELI)&nbsp;Lymphoma, the sixth cancer worldwide in terms of incidence, is a complex disease. ELI, The European Lymphoma Institute, regroups top European specialists in the field of lymphoma within a net dedicated to research, training and education. To date, thirteen European academic research groups have come together in an effort to define strategies to analyze and characterize this cancer, common diagnostic procedures and therapeutic standards as well as to facilitate clinical and fundamental research at the European level.&nbsp;

Lymphoma Hub Press Release Q1: Lymphoma Hub Maintains Its Focus On Raising The Levels Of Global Knowledge Of Lymphoma In 2022

The <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>, run by <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support</a> (SES) in partnership with the <a href="https://www.esh.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">European School of Haematology</a> (ESH), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in multiple myeloma (MM). The Multiple Myeloma Hub has continued to promote significant developments in the treatment and research of MM throughout Q1 of 2022.&nbsp;The Multiple Myeloma Hub covered two key conferences in Q1 of this year, ensuring the MM community receive the latest news and insights in MM treatment and research. In February, the hub virtually attended the 4th European CAR T-cell Meeting, providing live social media coverage of the conference, as well as articles summarizing key presentations. The hub also virtually attended the 48th Annual Meeting of the EBMT, providing live coverage, expert interviews, and summary articles.&nbsp;The coverage provided for these congresses helped generate over 65,000 page views for the hub in Q1 and generated over 129,000 impressions on the social channels.&nbsp;&nbsp;&nbsp;Reviewing the Multiple Myeloma Hub’s impact this quarter, Marta Llobet Canela, Multiple Myeloma Content Lead at Scientific Education Support, said:&nbsp;“This quarter has been an especially busy period for the Multiple Myeloma Hub. As part of our commitment to continuously enhance the hub’s user experience, we introduced new digital innovations, including article learning objectives and interactive quizzes that test a user’s pre- and post-knowledge when reading an article. We have also updated the hub with Google Translate, and as a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.&nbsp;“By attending key congresses and providing extensive coverage, we bring education to those who cannot attend and ensure that they are able to have sight of educational messages and vital updates in MM.&nbsp;“Activity such as this would not be possible without our supporters. We would like to take this opportunity to show our gratitude to our existing supporters—Pfizer, Sanofi, AbbVie, Bristol Myers Squibb, Genentech, Roche, Amgen, Oncopeptides, Takeda, and Karyopharm Therapeutics. We would also like to thank our steering committee for their continued guidance and support.”&nbsp;ENDS&nbsp;For more information on the Multiple Myeloma Hub, please visit <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">multiplemyelomahub.com</a>.&nbsp;For media enquiries or to explore collaboration opportunities, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a> or <a href="mailto:Barry.Connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Barry.Connolly@scientificeducationsupport.com</a>.&nbsp;NOTES TO EDITOR&nbsp;About multiple myeloma (MM)&nbsp;Multiple myeloma (MM) is a form of blood cancer that begins with aberrant plasma cells—a type of white blood cell—in the bone marrow. It's called MM as it frequently affects several bones in the body, including the spine, skull, pelvis, and ribs, preventing the bone marrow from producing enough healthy blood cells while damaging and weakening the affected bones. MM accounts for 15% of all blood malignancies and 2% of all cancers.&nbsp;About the Multiple Myeloma Hub&nbsp;The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MM. Our aim is to enhance knowledge of MM through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.&nbsp;The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the Multiple Myeloma Hub supports HCPs worldwide.&nbsp;Founded in partnership with the European School of Haematology (ESH) in 2017, the Multiple Myeloma Hub is guided by an international <a href="https://multiplemyelomahub.com/steering-committees/steering-committee" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">steering committee</a> of experts in the field of MM. The steering committee meet regularly to discuss the performance of the Multiple Myeloma Hub and to devise action plans on how best to support the MM community and address any unmet educational needs.&nbsp;Multiple Myeloma Hub supporters&nbsp;Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.&nbsp;<ul><li>Pfizer&nbsp;</li><li>Sanofi&nbsp;</li><li>AbbVie&nbsp;</li><li>Bristol Myers Squibb&nbsp;</li><li>Genentech&nbsp;</li><li>Roche&nbsp;</li><li>Amgen&nbsp;</li><li>Oncopeptides&nbsp;</li><li>Takeda&nbsp;</li><li>Karyopharm Therapeutics&nbsp;</li></ul>If you are interested in becoming a Multiple Myeloma Hub supporter, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a>.&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, and <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>.&nbsp;About the European School of Haematology (ESH)&nbsp;The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in haematology.&nbsp;

Press Release for the Multiple Myeloma Hub Q1.

Asset 2.png

Multiple Myeloma Hub Press Release Q1: Multiple Myeloma Hub continues to enhance global knowledge of myeloma throughout 2022 

The <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>, run by <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support (SES)</a> in partnership with the <a href="https://www.leukemia-net.org/content/home/index_eng.html" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">European LeukemiaNet (ELN)</a>, is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in myeloproliferative neoplasms (MPN). During the first quarter of 2022, we continued to promote significant developments in the treatment of MPN through coverage of a prominent congress.&nbsp;In March, the MPN Hub virtually attended the <a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt%22%20HYPERLINK%20%22https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">48th Annual Meeting of the EBMT</a>, where we provided live updates on social media, conducted expert interviews, and developed congress-related summary articles for our audience. This activity contributed to the hub receiving over 20,000 page views and just over 4,400 visitors during Q1, as well as 37,000 impressions on our social channels.&nbsp;During Q1, the MPN Hub also published two visual abstracts. The first summarized key efficacy and safety results from the phase II <a href="https://mpn-hub.com/medical-information/navitoclax-add-on-to-ruxolitinib-in-patients-with-myelofibrosis-latest-data-from-the-phase-ii-refine-trial" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">REFINE trial</a>, in which navitoclax was added to ruxolitinib in patients with myelofibrosis. The second presented results from the phase II <a href="https://mpn-hub.com/medical-information/visual-abstract-a-study-to-evaluate-the-efficacy-and-safety-of-pemigatinib-incb054828-in-subjects-with-myeloidlymphoid-neoplasms-with-fgfr1-rearrangement-fight-203" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">FIGHT-203 study</a>, evaluating the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement.&nbsp;Reviewing the MPN Hub’s impact this quarter, Gizem Karakuleli, MPN Hub Content Lead at Scientific Education Support, said:&nbsp;“We were delighted to virtually attend the 48th Annual Meeting of the EBMT, where our team provided extensive coverage and reviewed some of the latest treatment and research areas of interest for the MPN community. Having a dedicated team at this virtual event allowed us to provide our audience with live congress commentary on the latest insights and findings in the field. Our coverage for the event performed especially well on our social channels, where we focussed on outcomes of cellular therapy in different types of MPN, such as blast phase MPN and chronic neutrophilic leukemia.&nbsp;&nbsp;“As part of our commitment to continuously enhance the hub’s user experience, we have introduced new digital innovations, including article learning objectives and interactive quizzes, which test a user’s pre- and post-knowledge when reading an article. We have also updated the hub with Google Translate, and as a result, the content can be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.&nbsp;“We would like to thank the MPN Hub Steering Committee and our supporters—Bristol Myers Squibb, AbbVie, CTI BioPharma, Novartis, Kartos Therapeutics, AOP Orphan, Constellation Pharmaceuticals, Geron, and Sierra Oncology—without whom our work would not be possible.”&nbsp;ENDS&nbsp;For more information on the MPN Hub, please visit <a href="http://www.mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">mpn-hub.com</a>.&nbsp;For media enquiries or to explore opportunities for collaboration, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a> or <a href="mailto:Barry.Connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Barry.Connolly@scientificeducationsupport.com</a>.&nbsp;About myeloproliferative neoplasms (MPN)&nbsp;Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers where the body produces too many red blood cells, white blood cells, or platelets. The three main types include myelofibrosis, polycythemia vera, and essential thrombocythemia.&nbsp;About the MPN Hub&nbsp;The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge of MPN through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.&nbsp;The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the MPN Hub supports HCPs worldwide.&nbsp;Founded in partnership with the European LeukemiaNet (ELN) in 2020, the MPN Hub is guided by an international <a href="https://mpn-hub.com/steering-committees/steering-committee" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">steering committee</a> of experts in the field of MPN. The steering committee meet regularly to discuss the performance of the MPN Hub and to devise action plans on how best to support the MPN community and address any unmet educational needs.&nbsp;MPN supporters&nbsp;Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.&nbsp;<ul><li>Bristol Myers Squibb&nbsp;</li><li>AbbVie&nbsp;</li><li>CTI BioPharma&nbsp;</li><li>Novartis&nbsp;</li><li>Kartos Therapeutics&nbsp;</li><li>AOP Orphan&nbsp;</li><li>Constellation Pharmaceuticals&nbsp;</li><li>Geron&nbsp;</li><li>Sierra Oncology&nbsp;</li></ul>If you are interested in becoming an MPN Hub supporter, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a>.&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company providing projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through the Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hematological-oncology: the <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, and <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>.&nbsp;About The European LeukemiaNet&nbsp;220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.&nbsp;

group1.png

MPN Hub Press Release Q1: The Mpn Hub Continues to Provide The Latest Treatment And Research Updates In The Field Of Myeloproliferative Neoplasms

The <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, run by <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support (SES)</a> in partnership with the <a href="https://www.leukemia-net.org/content/home/index_eng.html" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">European LeukemiaNet (ELN)</a>, is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in acute myeloid leukemia (AML). In Q1 of 2022, the AML Hub continued to provide coverage of key conferences and the latest scientific literature, as well as produce expert interviews and clinical trial updates in the field of AML.&nbsp;During Q1, the hub provided extensive coverage of the 48th Annual Meeting of the EBMT, including live social coverage, expert interviews, and summary articles. Our coverage focussed on the latest updates for conditioning, pediatrics, measurable residual disease, chimerism, relapse, and immune reconstitution. As a result of our activity, the hub received just under 30,000 page views this quarter and just over 7,000 users. Our social coverage also resulted in close to 120,000 impressions on our channels, with over 1,500 engagements. These metrics indicate that our target audience are finding our congress coverage insightful and relevant to their particular interests in AML research and treatment.&nbsp;The AML Hub also released two visual abstracts during Q1: one presenting data from the <a href="https://aml-hub.com/medical-information/visual-abstract-azacitidine-lenalidomide-and-dli-as-salvage-therapy-for-mds-cmml-and-saml-after-allo-hsct-azalena" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AZALENA study</a>, which investigated azacitidine, lenalidomide, and donor lymphocyte infusion as salvage therapy for MDS, CMML, and secondary AML after allo-HSCT; and the other presenting key data from the phase III <a href="https://aml-hub.com/medical-information/visual-abstract-or-agile-study-of-ivosidenib-azacitidine-versus-placebo-azacitidine-in-newly-diagnosed-patients-with-an-idh1-mutation" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AGILE study</a>, which evaluated ivosidenib + azacitidine versus placebo + azacitidine in patients with previously untreated IDH1-mutant AML.&nbsp;Reviewing the AML Hub’s impact this quarter, Claire Aukim-Hastie, Director of Scientific Services, Scientific Education Support, said:&nbsp;“In Q1 of 2022, the AML Hub continued to successfully navigate the virtual climate, remotely covering the 48th Annual Meeting of the EBMT. For the congress, we provided a combination of live and on demand social media coverage of key sessions and conducted interviews with experts in the field of AML. As part of our commitment to continuously enhance the hub’s user experience, we also introduced a new digital innovation with the addition of Google Translate to the hub. As a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.&nbsp;“The AML Hub owes thanks to its steering committee members and supporters—Roche, Genentech, AbbVie, Amgen, Novartis, Bristol Myers Squibb, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Gamida Cell, Pfizer, Syndax, and Thermo Fisher Scientific, the first diagnostic company to join the hub’s supporter network—without whom our work would not be possible.”&nbsp;ENDS&nbsp;For more information on the AML Hub, please visit <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">aml-hub.com</a>.&nbsp;For media enquiries or to explore collaboration opportunities, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a> or <a href="mailto:Barry.Connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Barry.Connolly@scientificeducationsupport.com</a>.&nbsp;About acute myeloid leukemia (AML)&nbsp;AML is a form of blood cancer originating in the bone marrow and is caused by an uncontrolled expansion of immature stem cells of myeloid lineage. It is the most common acute leukemia in adults and increases in incidence with age.&nbsp;Understanding the molecular changes associated with the progression of AML has led to risk stratification and promising new targeted therapies. However, the only potentially curative option is allogeneic hematopoietic stem cell transplantation, which has become more readily available and safer owing to reduced-intensity conditioning regimens.&nbsp;About the AML Hub&nbsp;The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on AML. Our aim is to enhance knowledge of AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.&nbsp;&nbsp;The AML Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the AML Hub supports HCPs worldwide.&nbsp;Founded in partnership with the European LeukemiaNet (ELN) in 2016, the AML Hub is guided by an international <a href="https://aml-hub.com/steering-committees/executive-steering-committee" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">steering committee</a> of experts in the field of AML. The steering committee meet regularly to discuss the performance of the AML Hub and to devise action plans on how best to support the AML community and address any unmet educational needs.&nbsp;AML Hub supporters&nbsp;Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.&nbsp;<ul><li>Pfizer&nbsp;</li><li>Genentech&nbsp;</li><li>Roche&nbsp;</li><li>AbbVie&nbsp;</li><li>Amgen&nbsp;</li><li>Novartis&nbsp;</li><li>Bristol Myers Squibb&nbsp;</li><li>Syndax&nbsp;</li><li>Janssen Oncology&nbsp;</li><li>Jazz Pharmaceuticals&nbsp;</li><li>Gamida Cell&nbsp;</li><li>Thermo Fisher Scientific&nbsp;</li></ul>If you are interested in becoming an AML Hub supporter, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a>.&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>, and <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>.&nbsp;About the European LeukemiaNet&nbsp;220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.&nbsp;

AML Hub Press Release Q1: The AML Hub Increases Congress Coverage to Provide Latest Developments In Acute Myeloid Leukemia Treatment And Research

The <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, run by <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support (SES)</a> in partnership with the <a href="https://www.leukemia-net.org/content/home/index_eng.html" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">European LeukemiaNet (ELN)</a>, is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in myelodysplastic syndromes (MDS). During Q1 of 2022, the MDS Hub continued to share latest advancements related to MDS, including updates from ongoing clinical trials and information on cutting-edge discoveries in treatments and therapeutic regimens.&nbsp;In March, the MDS Hub provided extensive coverage of the <a href="https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt%22%20/h%20%20HYPERLINK%20%22https://www.ebmt.org/events/virtual-48th-annual-meeting-ebmt" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">48th Annual Meeting of the EBMT</a> through live social media updates, expert interviews, and summary articles. This coverage contributed to the hub receiving over 7,200 views and 1,200 visitors during Q1. The impact of our coverage on social media was also evident, with our social channels receiving over 20,000 impressions during the quarter.&nbsp;During Q1 of 2022, we also produced two visual abstracts: the first presented key data from a study evaluating lenalidomide and eltrombopag for treating symptomatic anemia in patients with low- or intermediate-risk MDS; and the second summarized data from the AZALENA trial, investigating azacitidine, lenalidomide, and donor lymphocyte infusion as salvage therapy for MDS, chronic myelomonocytic leukemia, and secondary AML after allo-HSCT.&nbsp;Reviewing the MDS Hub’s impact this quarter, Claire Aukim-Hastie, Director of Scientific Services, Scientific Education Support, said:&nbsp;“During this quarter, we attended the 48th Annual Meeting of the EBMT and updated our audience with advancements in the field of MDS. Some of the key areas that we covered included autologous immune cells in cellular therapy, protective donor genotypes, graft-versus-host disease, conditioning, and pediatrics. Our comprehensive coverage gives those who are unable to attend the conference instant updates and key insights into the latest research and treatment methods for MDS.&nbsp;“As part of our commitment to continuously enhance the hub’s user experience, we have introduced new digital innovations, including learning objectives and interactive quizzes to test a user’s knowledge before and after viewing our content. We have also updated the hub with Google Translate, and as a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.&nbsp;“We would like to take this opportunity to show our gratitude for our expert steering committee and existing supporters—Novartis, Bristol Myers Squibb, Janssen Oncology, Geron, and Takeda—without whom this continued activity would not be possible.”&nbsp;ENDS&nbsp;For more information on the MDS Hub, please visit <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">mds-hub.com</a>.&nbsp;For media enquiries, or to explore collaboration opportunities, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a> or <a href="mailto:Barry.Connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Barry.Connolly@scientificeducationsupport.com</a>.&nbsp;About myelodysplastic syndromes (MDS)&nbsp;Myelodysplastic syndromes (MDS) refer to a group of hematopoietic disorders that result in the production of insufficient numbers of healthy blood cells, along with changes in bone marrow morphology and, eventually, overall failure of the bone marrow. Progression of MDS can be indolent or aggressive, and some patients may go on to develop acute myeloid leukemia.&nbsp;About the MDS Hub&nbsp;The MDS Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MDS. Our aim is to enhance knowledge of MDS through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.&nbsp;The MDS Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the MDS Hub supports HCPs worldwide.&nbsp;Founded in partnership with the European LeukemiaNet (ELN) in 2020, the MDS Hub is guided by an international <a href="https://mds-hub.com/steering-committees/steering-committee" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">steering committee</a> of experts in the field of MDS. The steering committee meet regularly to discuss the performance of the MDS Hub and to devise action plans on how best to support the MDS community and address any unmet educational needs.&nbsp;MDS Hub supporters&nbsp;Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.&nbsp;<ul><li>Novartis&nbsp;</li><li>Bristol Myers Squibb&nbsp;</li><li>Geron&nbsp;</li><li>Takeda&nbsp;</li><li>Janssen Oncology&nbsp;</li></ul>If you are interested in becoming an MDS Hub supporter, please contact <a href="mailto:secretariat@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">secretariat@scientificeducationsupport.com</a>.&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company with projects such as community physician education though our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>, and <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>.&nbsp;About the European LeukemiaNet&nbsp;220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.&nbsp;

Asset 7.png

MDS Hub Press Release Q1: The MDS Hub Continues To Enhance Global Knowledge Of Myelodysplastic Syndromes Throughout Through Key Congress Coverage In 2022

May is Oncology Nursing Month – it's important to acknowledge the vital role oncology nurses play in the HCP community when it comes to patient treatment, advocacy, and care.&nbsp;Oncology nurses facilitate communication between physicians, patients, and caregivers. They help guide patients through their treatments, often providing comfort, information, and guidance.&nbsp;&nbsp;Nurses tend to be present across all indications of a patient’s treatment plan, which requires appropriate training and knowledge exchange in medical education.For Oncology Nursing Month, we reached out to oncology nurse, Erik Aerts, to hear his opinion on medical education on the topic of oncology nursing:&nbsp;In your experience does medical education cover specific therapy areas in oncology?&nbsp;“In my opinion, there are still gaps regarding the education for nurses and other HCPs. As therapies for oncology/hematology patients are more personalized and specific, education is not well covered in this area.”&nbsp;Do you feel like the patient voice is incorporated in medical education?&nbsp;“The voice of the patient is still underestimated; patients as well as their loved ones should be more involved in medical education.”&nbsp;What would you like to see more of in medical education that is directed at nurses?&nbsp;“Education for nurses could be increased regarding disease and symptom management, treatment and side effect management, and medication training. The role of nurses in medication management includes a variety of responsibilities, not only administration but also managing therapeutic and adverse effects, adherence, self-management, education, safety, and care transition.”&nbsp;Relevant literature: Liptrott S, NíChonghaile M, Aerts E, Heamatology Nurses and Healthcare Professionals Group (HNHCP). Investigating the self-perceived educational priorities of haematology nurses. Eur J Oncol Nurs. 2019;41:72-81. DOI: 10.1016/j.ejon.2019.05.010.&nbsp;Did you know SES’s IME is curated for all HCPs in their respective fields?&nbsp;“I wasn’t aware of SES and that it was targeted to all HCPs. It would be good to collaborate with other organizations, such as the Hematology Nurses &amp; Healthcare Professionals Group (HNHCP; www.hemcare.org).”Among our wide reach of HCPs, including hematologists, oncologists, researchers, and more, 10% of our global audience are nurses.Nurses play increasingly important roles in cancer care, from pre- and post-treatment management. A study published in the Journal of Clinical Oncology found that specialized oncology training for nurses resulted in better outcomes for patients with cancer, including lower hospital readmission rates, fewer treatment-related side effects, and improved quality of life.1&nbsp;Through our hubs, we provide microlearning modules geared towards physicians and nurses to improve patient outcomes, and our education is curated by world-renowned experts and guided by patient needs.&nbsp;&nbsp;We specialize in several therapeutic areas in the blood cancer arena, and our HCP education is tailored to address specific clinical practices, ranging from the latest treatments and clinical trials to drug updates, expert opinions, and more.&nbsp;Our patient programs <a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank">KnowAML</a> and <a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank">KnowALL</a>, are directed at patients, caregivers, and nurses to address concerns and advocate for patient best-practices, including disease and symptom management, access to the latest treatments, side effect management, and expert support.&nbsp;Thanks to our IME hubs and patient programs, we are uniquely positioned to incorporate the patient voice in our HCP education, this means that what is important to patients is important to us. Patients often form close bonds with nurses, lasting years post treatment. When considering medical education guided by patients, at SES we do the utmost to be easily accessible to a wide range of HCPs globally, including nurses.&nbsp;<a href="https://www.linkedin.com/company/scientific-education-support/" rel="noopener noreferrer" target="_blank">Follow SES</a> for the latest up-to-date IME delivered to all HCPs globally.Contact us to find out more about supporting opportunities:partnerships@scientificeducationsupport.comNathalie HolguinScientific Education Support<ol><li>Porter C, Haase J, Kelley KM, et al. Oncology certified nurses and their value to cancer care. J Clin Oncol. 2015;33(16).</li></ol>

MicrosoftTeams-image (68).png

Oncology Nursing Month: Collaboration

SES is excited to the announce the accreditation of its first continuing medical education (CME) event. As part of our range of bespoke education programs, we are launching a clinical trial club in myeloproliferative neoplasms (MPN) entitled “Novel agents for the treatment of advanced myelofibrosis (MF).” The first interactive discussion for the club, “BOREAS trial: Navtemadlin (KRT-232) vs best available therapy in relapsed/refractory MF,” will be accessible as a live webinar on July 19, 2022, 08:00 CST (15:00 CEST). This 60-minute event has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (<a href="http://www.ebac-cme.org/" rel="noopener noreferrer" target="_blank">EBAC</a>) for 1 hour of external CME credit. The EBAC has signed agreements with the majority of European countries and an agreement of mutual recognition of credits with the American Medical Association (AMA), providing opportunities for physicians and teams to participate in high-quality CME around the world. By launching accredited education, it is our aim to provide healthcare professionals with education that will maintain and improve standards of medical practice, ultimately improving patient outcomes, globally.&nbsp;<h2>What is accreditation and why is it important?&nbsp;</h2>Accreditation is the process by which a credible, independent body assesses the quality of a medical education program to provide assurance that it is appropriate, balanced, transparent, and effective. Many countries require healthcare professionals to partake in accredited CME activities throughout their career for maintenance of licensure and certification, membership of professional societies, and other professional privileges. The EBAC awards continuing education points as a sign of quality and independence for participation in educational activities. It’s accreditation system requires CME providers to base their education on a <a href="https://scientificeducationsupport.com/independent-education" rel="noopener noreferrer" target="_blank">needs assessment</a>, measure the <a href="https://scientificeducationsupport.com/updates/hub-innovations-outcomes-measurements" rel="noopener noreferrer" target="_blank">effectiveness of their educational activities</a>, design educational content that meets accepted standards of scientific integrity, and ensure that education is free of commercial bias and influence. SES is pleased to have met the requirements of this rigorous evaluation process with the design of its first CME event. Looking to the future, we aim to establish a portfolio of CME resources for healthcare professionals across our therapy areas of focus.&nbsp;<h2>Our first CME event&nbsp;</h2>Our first CME event is brought to you via the expertise of the <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank">MPN Hub</a>.&nbsp;Myelofibrosis is associated with a significant reduction in patients' quality of life and an increased risk of mortality. Available treatment options, excluding allogeneic stem cell transplantation, are mainly directed to disease-related symptoms and splenomegaly. While JAK inhibitors provide spleen control and symptom improvement for patients, response to treatment is often lost, and there is currently an unmet need for novel therapies to effectively target the disease at the level of the malignant stem cell. There is an ongoing effort to develop novel approaches with different modes of action to fulfil this need, and with such progress it is key that healthcare professionals understand novel targets, the mechanisms of action of new agents, and maintain up-to-date knowledge of the role of new agents in the therapeutic landscape.&nbsp;In this first clinical trial club, chaired by Laura Michaelis, trial investigator Haifa Kathrin Al-Ali will discuss the phase II and phase III clinical trials (NCT03662126) investigating the novel MDM2 inhibitor, navtemadlin (KRT-232), in patients with MF who relapsed on or are refractory to JAK inhibitors. Together, they will review results from the open-label phase II trial and consider what these findings and the ongoing randomized controlled phase III trial (BOREAS), investigating navtemadlin versus best available therapy in relapsed/refractory MF, mean for clinical practice. The agenda includes a live question and answer session, providing participants with the opportunity to interact with our world-renowned faculty. A pre- and post-event test will allow us to understand the outcomes of this event and will help inform the design of future education.&nbsp;&nbsp;<a href="https://mpnhub-cme.com/" rel="noopener noreferrer" target="_blank"><img src="https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/82a999ea059b96c45efd226caa7e530b.png" alt="MPN CTC Bolt-on social_4.png"></a><h3>Registration is now live!&nbsp;<a href="https://mpnhub-cme.com/" rel="noopener noreferrer" target="_blank">Sign up now</a> to secure your place.</h3>

June22_web update_EBAC accreditation.png

SES launches first accredited CME event 

SES Independent Medical Education hubs new drug and trial updates section

June22_web update_Drug Updates.png

IME hub innovations: Drug and trial updates section  

The Partnerships team will be out in full force at the upcoming hematology and immunology congresses, aiming to meet supporters and prospects of our platforms alike.Senior Partnerships Manager Geoff Jones recently attended the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022 in Paris, France. Geoff took meetings with current and prospective supporters of the Multiple Myeloma Hub, with the primary objective of providing updates on the platform. These included·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a recap of the Multiple Myeloma Hub benefits, including the insight and engagement opportunities for supporters on the platform; and·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a summary of Multiple Myeloma Hub new features, such as the learning outcome evaluation tool, interactive quizzes, and Google Translate, which enables the hub’s content to be translated into 100 different languages.Geoff also attended a number of key sessions within both the educational program and satellite symposia. Some highlight sessions included·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MMy life: your specialty, my world;·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iStopMM study – the impact of nationwide screening;·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Antibody-drug conjugates in relapsed/refractory multiple myeloma: from bench to bedside; and·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elevating standard of care in MM: unlocking the potential of novel BCMA combinations.We look forward to sharing our insights and experiences at the upcoming congresses in June.EULARPartnerships Director, Ken Zangina, will be in Copenhagen, Denmark, for the European Alliance of Associations for Rheumatology (EULAR) congress on June 1–3. We will be spending time at this event to grow the footprint of our new immunology platform—<a href="https://lupushub.com/" rel="noopener noreferrer" target="_blank">Lupus Hub</a>. Please reach out to Ken directly on <a href="mailto:ken.zangina@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">ken.zangina@scientificeducationsupport.com</a> should you wish to meet with him to discuss support of this platform.ASCO/EHAMembers of the Partnerships team will be available to meet in person on both sides of the Atlantic for the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) congresses on June 3–7 and June 9–12, respectively. We look forward to connecting with our industry partners and contacts and providing some fantastic updates from all of SES’ hematology platforms, particularly with regard to the latest 2022 engagement statistics.Please contact the partnerships team on <a href="mailto:partnerships@scientifceducationshupport.com" rel="noopener noreferrer" target="_blank">partnerships@scientifceducationshupport.com</a> should you wish to meet with the team at this event.Supporter update Psoriasis and Psoriatic Arthritis Hub&nbsp;As we approach the launch of this platform, we are pleased to announce UCB as a founding supporter of SES’ first IME resource within immunology. With a strong heritage in psoriasis and psoriatic arthritis, we are proud to have UCB supporting our efforts to deliver independent, evidence-based medical education addressing the unmet needs in these therapy areas.&nbsp;<a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank">ALL Hub</a>We are delighted to confirm that Amgen will be continuing its support of the ALL Hub. Amgen’s support of this platform has been steadfast since its inception and complements Amgen’s strong support for our <a href="https://acuteleuk.org/" rel="noopener noreferrer" target="_blank">Acute Leukemia Advocate Network (ALAN)</a> patient-focused collaboration—<a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank">Know ALL</a>. Along with our existing industry partners, Pfizer and Novartis, Amgen’s sponsorship of the ALL Hub is highly valued and enables the SES team to continue delivery of the fantastic recent&nbsp;innovations implemented on the platform.Bespoke educational opportunitiesWe are seeking grants from our existing and new industry partners to ensure that the following newly created bespoke educational initiatives have credible representation across the scope of therapies.“Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis”The clinical trials club is a live webinar series where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support healthcare professionals in understanding what the latest news means for clinical practice. They offer the ideal solution to address a key learning gap of “suboptimal knowledge of novel therapeutic targets in MPN.”“Sequencing of therapies in acute lymphoblastic leukemia (ALL)”This case-based symposium will discuss the issues linked with the sequencing of therapies for B- and T-cell ALL. A panel of selected ALL Hub key opinion leaders will discuss cases related to both types of the disease. Pre- and post-case discussion will help develop viewers’ understanding of the recommended treatment algorithm in these cases and viewer interactivity with the panel will help raise confidence and competence in their management of these diseases. We are seeking support from industry stakeholders to enable the delivery of this learning initiative.Please contact the Partnerships team on <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">partnerships@scientificeducationsupport.com</a> if you would like to learn more about supporting these educational initiatives.&nbsp;

Update of the partnerships activity from Scientific Education Support.

Partnerships update-May 2022

<a href="https://rareanaemias.org/" rel="noopener noreferrer" target="_blank">Rare Anaemias International Network (RAIN) </a>is a global, community-based ecosystem comprising patient advocacy associations and individuals supporting rare anaemias​.​ RAIN is focused on implementing activities that advocate for equal access to innovative therapies and medications​.​&nbsp;&nbsp;RAIN shares best practice and skills among members and acts as a forum for advice and guidance on a variety of issues affecting patients, such as the cost effectiveness of drugs and treatments, access issues, and much more.​ We campaign together, joining forces to amplify the voice of smaller organisations and to help patients and health professionals establish new patient support groups where they do not currently exist.&nbsp;So far in 2022, RAIN has provided an overview of rare anaemias, including signs and symptoms, and diagnosis, launching our monthly social media themes. We have also supported several awareness raising initiatives, including World Cancer Day, Rare Disease Day, International Health Awareness Day, Autoimmune Disease Awareness Month, Fanconi Anaemia Awareness Day, International Nurses Day, and World Blood Cancer Day.&nbsp;RAIN marked International Thalassemia Day (ITD) on 8th May by posting and promoting Thalassaemia International Federation’s campaign Be Aware. Share. Care: Working with the global community as one to improve thalassaemia knowledge across the RAIN social media channels.&nbsp;<img src="https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/166dc52555a5dac3b0c1689da54d1257.jpg" alt="INT TIF.jpg">Continuing into 2022, RAIN will be hosting a virtual educational member meeting and will continue to increase knowledge levels in the rare anaemias community through various social media themes, including available treatments, treatment barriers, trials, innovative therapies, and disease self-efficiency. We will also support various awareness initiatives, including Sickle Cell Disease Day and World Blood Donor Day in June.&nbsp;RAIN is pleased to announce and owes thanks to the independent support of its founding industry partners, Agios, Sanofi, and Immunovant, without whom the initiative would not be possible. RAIN would also like to thank our dedicated member organisations for their ongoing participation and support.&nbsp;Working in collaboration with the members, the RAIN initiative is delivered by Scientific Education Support (SES), who aim to build communities and networks to facilitate education through collaboration, ensuring that patients have access to the latest support and treatment options.&nbsp;&nbsp;For more information about RAIN activities, educational meetings, or supporter packages, please contact SES_RAIN@scientificeducationsupport.com.&nbsp;Connect with our social channels:&nbsp;Twitter: @rareanaemias&nbsp;Facebook:	@rareanaemias&nbsp;LinkedIn:	Rare Anaemias International Network&nbsp;Instagram: @rareanaemias&nbsp;

Update from the Rare Anaemias International Network (RAIN) which is a global, community-based ecosystem comprising patient advocacy associations and individuals supporting rare anaemias​.​ 

Rare Anaemias International Network supports International Thalassaemia Day on 8th May and welcomes new supporters in 2022 

An overview of the SES approach to meeting unmet educational needs in medical education. 

Our approach to effective educational design: From identifying gaps to improving outcomes 

<h2>Hub innovations: Outcomes measurements&nbsp;</h2>Evaluation is a <a href="https://scientificeducationsupport.com/updates/our-approach-to-effective-educational-design-from-identifying-gaps-to-improving-outcomes" rel="noopener noreferrer" target="_blank">key element</a> of any educational program (1). It is essential to understand how effective an educational activity has been in closing the practice gaps identified in the needs assessment. To evaluate changes in knowledge and competence, we design <a href="https://lymphomahub.com/medical-information/axi-cel-vs-soc-for-rr-lbcl-zuma-7-primary-analysis" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">pre- and post-activity questions</a> to ascertain whether our specific and measurable learning objectives have been met. The pre-activity test questions are identical to the post-activity test questions, so by using the pre-activity test responses as a baseline, we can measure improvements resulting from our education. For our hubs, these pre- and post-activity questions take the format of a “Quick Quiz” intended as a fun challenge for readers, providing them with the opportunity to test their knowledge, improve on their pre-activity quiz score, and compare themselves to the average score of their colleagues. As the first step in the role out of the <a href="https://scientificeducationsupport.com/updates/medical-education-hubs-digital-innovations-2022" rel="noopener noreferrer" target="_blank">Quick Quiz</a>, this functionality was introduced to the Lymphoma Hub earlier this year.&nbsp;Since the end of February 2022, we have published seven articles on the Lymphoma Hub that each include a precise learning objective and two pre- and post-activity questions. Initial data are encouraging, indicating high engagement and completion rates compared with conventional online content (2,3) and importantly, improvements in learners’ knowledge following review of our content.&nbsp;&nbsp;<h3>Key statistics&nbsp;</h3><ul><li>The engagement rate (number of page viewers that go on to play the quiz) has reached up to 24%.&nbsp;</li><li>For the seven articles published to date, the overall completion rate of the quizzes (percentage of readers who complete the quiz after initial engagement) is 73% (n = 62).&nbsp;&nbsp;</li><li>Importantly, of the completed quizzes, knowledge increased following engagement in 60% of the completed quizzes. No overall decrease in knowledge was recorded.&nbsp;&nbsp;</li><li>For quizzes where a knowledge increase was recorded, the average increase in knowledge was 49%.&nbsp;</li></ul>Excitingly, these data demonstrate the effectiveness of our education and the positive impact we are having on readers’ knowledge about specific elements of lymphoma management. The data will feed into our needs assessment process to ensure that we are continually optimizing our education. Analysis of the pre-activity test answers will help us to understand where educational needs are high, and analysis of the pre- and post-activity data will highlight whether our education is sufficiently addressing the needs identified in our needs assessment or whether further education is required in specific areas.&nbsp;&nbsp;Based on the success of the Quick Quiz on the Lymphoma Hub, we are excited to announce that quizzes are now available on all our hubs—<a href="https://multiplemyelomahub.com/medical-information/novel-risk-score-for-predicting-early-relapse-in-patients-with-multiple-myeloma" rel="noopener noreferrer" target="_blank">try our recent quiz on the Multiple Myeloma Hub</a>. Furthermore, we plan to introduce innovations to further increase engagement and provide benefits for individual users. At SES, our ultimate goal is to positively impact patient health; enhancing our capacity to measure and understand the outcomes of our education is a key step towards this goal.&nbsp;&nbsp;<ol><li>Shannon S. Education and practice. Needs assessment for CME. Lancet. 2003;361:974.&nbsp;</li><li>CXL. What is a “good” click-through rate? Click-through rate benchmarks. <a href="https://cxl.com/guides/click-through-rate/benchmarks/" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">https://cxl.com/guides/click-through-rate/benchmarks/</a>. Accessed May 24, 2022.&nbsp;&nbsp;</li><li>&nbsp;Grow my Ads. The GoogleAds benchmarks you need to know in 2022. <a href="https://growmyads.com/google-ads-benchmarks" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">https://growmyads.com/google-ads-benchmarks</a>. Accessed May 24, 2022.&nbsp;&nbsp;</li></ol>

An overview of the outcomes measurements SES have implemented for all medical education article content.

Hub innovations: Outcomes measurements 

After a busy first quarter attending virtual meetings, the Partnerships team is pleased to announce our in-person attendance at a series of hematology congresses in the coming months.&nbsp;COMy&nbsp;Our Senior Partnerships Manager Geoff Jones will be in Paris for the 8th World Congress on Controversies in Multiple Myeloma (COMy) on May 12–15. If you are attending the event and would like to know more about the Multiple Myeloma Hub—an SES and European School of Haematology (ESH) partnered platform—please <a href="mailto:Geoff.Jones@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">email Geoff Jones</a> directly.EULAR&nbsp;Partnerships Director Ken Zangina will be in Copenhagen for the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress on June 1–3 to grow the footprint for our new immunology platform, the Lupus Hub (lupushub.com). Please <a href="mailto:ken.zangina@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">email Ken Zangina</a> directly should you wish to meet to discuss supporting this platform.&nbsp;ASCO/EHA&nbsp;Members of the Partnerships team will be available to meet in person on both sides of the Atlantic for the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) congresses on June 3–7 and June 9–12, respectively. We look forward to connecting with our industry partners and contacts and providing some fantastic updates from our hematology platforms, particularly with regard to engagement statistics from Q1, 2022. Please <a href="mailto:partnerships@scientifceducationsupport.com" rel="noopener noreferrer" target="_blank">contact the partnerships team</a> on should you wish to meet at either of these events.&nbsp;<h2>Supporter Updates&nbsp;&nbsp;</h2><a href="https://rareanaemias.org/" rel="noopener noreferrer" target="_blank">RAIN&nbsp;</a>We are delighted to welcome Sanofi as the third founding supporter of the Rare Anaemias International Network (RAIN). RAIN is a global community-based ecosystem comprising patient advocacy associations and individuals supporting rare anemias​. With the first of two annual member meetings due to take place in the coming months, it is exciting to have a significant industry stakeholder in the treatment of Cold Agglutinin Disease (CAD) involved with the initiative. Growing the industry support for RAIN is critical to achieving its mission of improving the health and quality of life of people with rare anemias.&nbsp;<a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank">Multiple Myeloma Hub&nbsp;</a>We are delighted to confirm that AbbVie will be continuing their support of the <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank">Multiple Myeloma Hub</a>. As a Silver supporter, AbbVie’s sponsorship of this platform along with our existing industry partners is highly valued and enables the SES team to deliver significant innovations on the platform, such as the recent Google Translate feature, which helps to expand the hub’s global reach.&nbsp;&nbsp;<a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank">Lymphoma Hub&nbsp;</a>&nbsp;We are pleased to announce Daiichi Sankyo as confirmed supporters of the <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank">Lymphoma Hub</a> in 2022.&nbsp;The addition of this organization at Contributor level highlights the strong support that this platform continues to enjoy from industry partners. Content from the Lymphoma Hub reached 68,546 users in 2021, and we hope to build upon this footprint in 2022 with the development of exciting new features on the platforms. Meanwhile, we are focused on delivering quality, diverse content that is of value to the healthcare community in lymphoma and CLL.&nbsp;Bespoke Educational Opportunities&nbsp;We are seeking grants from our existing and new industry partners to ensure that the following newly created bespoke educational initiatives have credible representation across the scope of therapies.&nbsp;&nbsp;“Towards personalized therapy in relapsed multiple myeloma”&nbsp;This digital symposium will help users describe novel therapeutic targets in multiple myeloma and explain the mechanisms of action for new agents in the disease space. Users will also be able to&nbsp;state the rationale for selecting treatments in relapsed/refractory disease based on disease- and patient-related factors. The symposium will be designed in collaboration with the experienced and world-renowned Multiple Myeloma Hub Steering Committee to ensure relevance and accuracy in addition to attracting a big audience.&nbsp;“Beyond JAK inhibition: novel agents for the treatment of advanced myelofibrosis”&nbsp;This clinical trials club is a live webinar series where one of our steering committee members will be joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trials clubs effectively support healthcare professionals in understanding what the latest news means for clinical practice. This clinical trials club offers the ideal solution to address a key learning gap of “suboptimal knowledge of novel therapeutic targets in myeloproliferative neoplasms.”&nbsp;“How to select and sequence treatments for steroid-refractory GvHD”&nbsp;This interactive case study educational project will offer users the potential to transition from simple knowledge gains to changes in patient care outcomes in the management of this challenging patient group. Learners will be presented with a patient case, identified challenge, or specific decision, along with supporting data. The learner will be guided/coached by a leading expert based on their treatment decision and provided with the correct answer. After engaging with this content, we hope users will be able to explain the role of new agents in the graft-versus-host disease therapeutic landscape, including optimal patient selection and sequencing.&nbsp;Please <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">contact the Partnerships team</a> on if you would like to learn more about supporting these educational initiatives.&nbsp;

Overview of SES Partnership activity -April 2022

April newsletter images 0.1_Partnerships_web.png

Partnerships Updates-April 2022

Spring steering committee meetings&nbsp;Our IME hubs are guided by international steering committees of world-leading experts in their respective therapy areas. These committees meet regularly to discuss educational content and how to support their communities. One way they achieve this is through two steering committee meetings each year, which are hosted by their chairperson and SES.&nbsp;&nbsp;Each meeting serves as an opportunity for the steering committee to gain insights on current hub metrics such as global growth, evaluate educational impact, and hear about new hub innovations.&nbsp;The members also take part in an open discussion on a specific topic of their choosing. This topic is one they believe is affecting the therapy area, the HCPs who practice within it, and the patients that require the care. With a global representation of leading professionals coming together, these discussions provide a unique view of the therapy area, as well as different insights into successful practice. The discussions from these meetings are published on the hubs as enduring content for the wider community to view and learn from.&nbsp;How can you get involved? At certain levels of support, we offer the opportunity for our industry partners to sit in and listen to these discussions in real-time as an observer. Hearing these conversations take place demonstrates to industry what is important to those they aim to support. Following each meeting, all supporters also receive a summary report noting important aspects of the meeting.&nbsp;If you would like to know more about our steering committee meetings or how you can be involved, please contact partnerships@scientificeducationsupport.com&nbsp;Supporter update &nbsp;SES would like to thank the following companies for their new and continued support of independent medical education.&nbsp;Lymphoma Hub and Multiple Myeloma Hub CAR T symposium at EHA2023&nbsp;&nbsp;BMS funded an accredited symposium at EHA2023 on CAR T in lymphoma and multiple myeloma, which reached full capacity at the live event. In the coming weeks, catch up on enduring content captured from this symposium via the Lymphoma Hub and Multiple Myeloma Hub.&nbsp;Know AML&nbsp;&nbsp;BMS will be continuing their support for the Know AML patient platform as a Gold supporter. BMS’s support of this platform facilitates the great work the Know AML team achieves and will continue to do so.&nbsp;&nbsp;Know ALL&nbsp;&nbsp;Jazz Pharmaceuticals have continued their support of the Know ALL platform as a Bronze supporter. Supporting patient programmes as well as HCP IME platforms shows a clear path of support for the ALL community.&nbsp;&nbsp;Amgen have once again shown their commitment to patients with ALL by continuing their Bronze support of the Know ALL platform.AML Hub&nbsp;&nbsp;Pfizer have been an active supporter of the AML Hub since 2021 and we are delighted to welcome their continued support of the AML Hub at Bronze level through 2024.&nbsp;&nbsp;We are delighted to share that Daiichi Sankyo will be supporting the AML Hub at Silver level, enabling our team to meet the educational objectives set by the steering committee.&nbsp;We are proud to announce new support from GlycoMimetics for the AML Hub. Glycomimetic are the first alternative pharmaceutical supporter for the AML Hub and we welcome them at Bronze level.&nbsp;ALL Hub&nbsp;&nbsp;Jazz Pharmaceuticals have shown their support for the ALL Hub at Silver level, helping elevate education and awareness within the ALL HCP community.&nbsp;&nbsp;GvHD Hub&nbsp;&nbsp;After the Sanofi takeover of Kadmon in 2021 they quickly saw the benefits of the GvHD Hub that Kadmon had previously. In fact, they saw such value that their support was increased from Silver to Gold. We welcome Sanofi and their support of the GvHD Hub.&nbsp;Lymphoma Hub&nbsp;The Lymphoma Hub is our largest and most established IME platform, drawing in tens of thousands of visitors from around the globe. This year, we are very pleased that Eli Lily have continued their Bronze support and continue to help the platform grow.&nbsp;BMS have been supporters of the Lymphoma Hub for several years and have once again shown their dedication by continuing their support at Bronze level.&nbsp;We are delighted that Roche have continued to be the leading supporter of the Lymphoma Hub by renewing their Gold support, ensuring the hub is maintained as a leading resource for HCPs seeking the latest updates in lymphoma.&nbsp;&nbsp;Multiple Myeloma Hub&nbsp;&nbsp;Abbvie are an established supporter of Multiple Myeloma Hub; they have continued their support at Silver level, providing the hub the ability to continue to produce excellent content.

SES Jun23 Webupdate_supporter thanks.png

Partnerships update - steering committee meetings and supporter update

In September 2023, Know AML marked Blood Cancer Awareness Month; this is a time when people from around the world come together to help raise awareness of blood cancer.&nbsp;This year’s campaign, #TalkAML, aimed to empower the acute myeloid leukemia (AML) community by encouraging dialogue around the importance of provision and access to mental health and wellbeing support for patients, caregivers, and healthcare professionals.&nbsp;During this time, Know AML reached an impressive 94 countries, received 10,984 page views, and achieved a watch time of 359.8 hours on YouTube.&nbsp;On September 20, 2023, Know ALL marked the second World Acute Lymphoblastic Leukemia (ALL) Day; this is a time when patients and caregivers from all around the world come together to help raise awareness of ALL. This year’s campaign aimed to raise awareness of this cancer and educate people on why knowledge of ALL subtypes is important for treatment planning, the different ALL subtypes and how they are classified among the community, and to share their subtype and experience of ALL with others.&nbsp;&nbsp;The #WorldALLDay hashtag reached over 174,000 impressions on X, while the Know ALL website reached 44 countries and 2,778 page views.&nbsp;

SES Partnerships updates Oct232_webupdate_1.png

Know AML and Know ALL 2023 awareness initiatives

After 10 years working between hospital and community pharmacy, I opted for a move to medical education as I have always felt passionate about HCP education and patient empowerment, having experienced it first-hand. With a year as a Project Manager on the <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank">AML </a>and <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank">MDS</a> Hubs, as well as the <a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank">Know AML</a> patient program, I have been exposed to the impactful and crucial work SES produces in the independent medical education space. I now look forward to assisting our HCP and patient advocacy communities to lift their knowledge in HemOnc and Immunology, through our exciting and up-to-date platforms, in my new position as Business Development Manager with SES.&nbsp;&nbsp;I will be attending the&nbsp;<a href="https://www.esh.org/conference/6th-international-conference-acute-myeloid-leukemia-molecular-and-translational-advances-in-biology-and-treatment/" rel="noopener noreferrer" target="_blank" style="color: windowtext;">6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment&nbsp;</a>Estoril, Portugal29-31 October&nbsp;Get in touch to meet me at #ESHAML2023:&nbsp;<a href="mailto:Danielle.Ferrie@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Danielle.Ferrie@scientificeducationsupport.com</a> Danielle FerrieScientific Education Support

SES Aug23 Webupdate image_Dani.png

Welcome to the team, Danielle Ferrie!

Created in partnership with the Federation of Clinical Immunology Societies (<a href="https://www.focisnet.org/" rel="noopener noreferrer" target="_blank">FOCiS</a>), the <a href="https://lupushub.com/" rel="noopener noreferrer" target="_blank">Lupus Hub</a> launched in October 2022 thanks to support from our founding supporters, <a href="https://www.astrazeneca.co.uk/" rel="noopener noreferrer" target="_blank">AstraZeneca</a> and <a href="https://www.gsk.com/en-gb/" rel="noopener noreferrer" target="_blank">GSK</a>.&nbsp;&nbsp;Chaired by Professor <a href="https://www.clinicbarcelona.org/en/professionals/ricard-cervera" rel="noopener noreferrer" target="_blank">Ricard Cervera</a>, Hospital Clínic de Barcelona, Barcelona, ES, this platform delivers open-access education that is informed by patients, curated by world leaders, and endorsed by expert societies—supporting healthcare professionals (HCPs) worldwide.&nbsp;&nbsp;Currently, with 2.2k unique users across 100 countries, the platform provides HCPs and researchers with instant access to expert opinions and the latest evidence-based information on lupus, to aid in treatment decisions and, ultimately, improve the lives of patients with lupus globally.&nbsp;“We have been working very hard over the last year at the Lupus Hub.&nbsp;&nbsp;&nbsp;The Lupus Hub aims to deliver valuable, up-to-date information on the most exciting advances in lupus, making the hub a go-to site for all HCPs in this space. In order to reach this objective, we have included up-to-date information on the most recent trials on potential new drugs for lupus, including telitacicept, dapirolizumab pegol, zetomipzomib, baricitinib, and deucravacitinib. Also, we have included additional information on recently approved drugs for lupus, such as voclosporin and anifrolumab, and the new indications (lupus nephritis) for belimumab, the first biological drug approved for lupus; CD19 CAR T-cell therapy has also received special attention at the Lupus Hub.&nbsp;&nbsp;&nbsp;We have also covered the <a href="https://www.eular.org/" rel="noopener noreferrer" target="_blank">EULAR </a>and <a href="https://rheumatology.org/annual-meeting" rel="noopener noreferrer" target="_blank">ACR Convergence</a> congresses and produced a webinar on low lupus disease activity versus remission as treat-to-target goals in lupus, with the participation of our steering committee members.”&nbsp;&nbsp;&nbsp;&nbsp;- Professor Ricard Cervera, Hospital Clínic de Barcelona, Barcelona, ES.&nbsp;<img src="https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/773a3e91d021173c71c8d836141e8f23.png" alt="Picture1.png">

SES_Oct23_Webupdate_Lupus1st.png

Happy 1st birthday to the Lupus Hub!

June has been an exciting month for Scientific Education Support (SES), with fantastic activities and updates from a busy period of major hematology congresses.The Partnerships team took the opportunity to attend ASCO in Chicago and EHA in Vienna and experienced some fantastic interactions with new and existing supporters. We were able to highlight key developments on the platforms and from the content coverage plans in the coming months, particularly regarding our hot topics abstract lists for the hubs.We asked Senior Partnership Managers, Geoff Jones and Emma Williams, for their review and conclusions of these congresses.“Attending EHA was a great opportunity and a first conference experience representing SES. Highlights were being able to meet with key supporters for the MM and MDS platforms in person and highlighting our great work in delivering upon the educational objectives of the platforms, particularly increasing knowledge of novel targets and mechanisms of action for agents within the therapy space. The learning opportunities from the scientific sessions were of excellent value, especially with the backdrop of a beautiful city like Vienna.” — Geoff Jones“For my first congress experience representing SES, it was wonderful to finally meet so many key supporters and contacts. It provided the ideal opportunity discuss the expansion of our platforms, particularly in acute leukaemia and our focus on the topic of MRD and effectively utilizing next-generation sequencing to aid personalised treatment plans. I also took the opportunity to discuss some the exciting bespoke CME projects, which we are launching from July onwards. Having attended several sessions, I was left fascinated by the amazing innovation demonstrated within haematology.” — Emma WilliamsThe Partnerships team look forward to continuing our discussions as we move into the summer. The planning now begins for SES presence in New Orleans for the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in December.Supporter updatesAML Hub We are delighted to confirm that Syndax will be continuing its support of the AML Hub. As a Bronze supporter, Syndax’s support will contribute towards enabling the team to meet the key educational objectives of the platform, including stating the best practice use of novel agents in AML.MDS HubWe are delighted to announce that Thermo Fisher Scientific will be supporting the MDS Hub as a Bronze supporter. As a key supporter of the sister platform, AML Hub, we’re encouraged to see Thermo Fisher Scientific widen their existing support to this key learning resource for clinicians treating myelodysplastic syndromes. Thermo Fisher Scientific now join BMS and Janssen as key supporters of this platform.Lymphoma HubWe are pleased to welcome AstraZeneca to the supporter group of the Lymphoma Hub. As a key stakeholder within the treatment of CLL, we are delighted to have AstraZeneca joining the key industry stakeholders in providing support to the biggest platform within SES’s hematology franchise.Bespoke educational opportunitiesWe are seeking grants from our existing and new industry partners to support the delivery of new and innovative educational learning interventions for the hematology community. Through the delivery of these bespoke initiatives across our established learning platforms, we hope to demonstrate advanced levels of learning in targeted areas of unmet needs relevant to healthcare professionals.&nbsp;CAR T-cell therapy: Cross-platform webinar series (Lymphoma, Multiple Myeloma, and ALL Hubs) In a first for the hematology hubs, this series of webinars will address unmet educational needs pertaining to the growing scope of CAR T-cell therapies across the hematology indications. With consideration of the complex treatment journey from the initial consultation through to transition of care, this project aims to support healthcare professionals involved in this new and evolving treatment area, enabling them to make optimal treatment choices for their patients. Leveraging the remarkable reach of three hub platforms, the content will also remain on the platforms as a valuable source of enduring content.Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosisThis clinical trial club is a live webinar series where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support healthcare professionals in understanding what the latest news means for clinical practice. They offer the ideal solution to address a key learning gap of “suboptimal knowledge of novel therapeutic targets in MPN.”Sequencing of therapies in acute lymphoblastic leukemia (ALL)This case-based symposium will discuss the issues linked with the sequencing of therapies for B- and T-cell ALL. A panel of selected ALL Hub key opinion leaders will discuss cases related to both types of the disease. Pre- and post-case discussion will help develop viewers’ understanding of the recommended treatment algorithm in these cases and viewer interactivity with the panel will help raise confidence and competence in their management of these diseases. We are seeking support from industry stakeholders to enable the delivery of this learning initiative.Please contact the Partnerships team on <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">partnerships@scientificeducationsupport.com</a> if you would like to learn more about supporting these educational initiatives.

June22_web update_Partnerships Update.png

Partnerships update-June 2022

Our Managing Director, Mia Hill, was selected to sit on the panel of the latest Good CME Practice Group (gCMEp) webinar. The webinar,&nbsp;Measuring outcomes: current expectations and practice,&nbsp;took place on Thursday 23 March 2023, 13.00–13.30 CET, and a recording is available here: <a href="https://gcmep.org/" rel="noopener noreferrer" target="_blank">https://gcmep.org/</a>. To find out more about what the webinar covered, please read on: Much is discussed about best practices when it comes to designing education and measuring outcomes, many people are familiar with the theory of Moore’s Outcomes Framework and the “levels of outcomes”; however, what is actually done in practice in Europe? How is it implemented and what are the expectations of education providers and the various stakeholders? What do accreditors require? What do grantors request? Is it OK to just report participation and satisfaction results? Or are providers going deeper into the data they collect?The panel reviewed and discussed some trends they are seeing in Europe and took questions from the audience along the way. The webinar is for anyone interested in how CME-CPD/IME is developed and presented in Europe.We are proud that SES is seen as a leader in the field of outcomes development and that the gCMEp chose Mia as a panellist for this session. &nbsp;Nathalie HolguinScientific Education Support

SES_March23_WebUpdate_1.png

gCMEp webinar - Measuring outcomes: current expectations and practice

At SES, we recently hosted our first webinar, with the aim of educating our industry supporters on the importance of incorporating the patient voice within IME.The 45-minute webinar included the thoughts and opinions of:&nbsp;<ul><li>Carl Harrington (a patient with Waldenstrom’s macroglobulinemia [WM] and past President and Chairman of the Board for the IWMF),​ who expressed his mission was to support all patients with WM and that it’s incredibly important to have the opportunity to advocate for the patient voice.&nbsp;&nbsp;</li><li>Lyndsy Ambler (a patient representative on the Lupus Hub Steering Committee)​, who wants a holistic approach to the input of IME, as patients have the best insight into understanding the reality of living with the condition.&nbsp;&nbsp;</li><li>Ricard Cervera (Lupus Hub Chair and Head of the Department of Autoimmune Diseases, Hospital Clínic, Barcelona), who explained how regarding lupus, his hospital is a champion in incorporating the patient voice, describing it as paramount importance and how it has enabled him to uncover two types of manifestations within patients; the second being Type 2: fatigue, aches and pains, and brain fog. ​&nbsp;&nbsp;</li><li>Cheryl Petruk (MPN–PAG Collaborative Steering Committee member), who was the sole carer for her husband who sadly passed from MPN. Cheryl expressed that it is vitally important to include patients in all communications as it is their choice and their life.</li></ul>The panel discussed from their perspective the key points to take note of regarding the logistics of making the above a reality, and shared examples of how SES are supporting them in doing this via our educational initiatives. Please follow the link below to watch the discussion take place!Carl: “SES has been a perfect partner in helping us achieve our goals in global patient initiatives and expanding doctor awareness, followed by patient awareness”.&nbsp;Cheryl: “Through SES and our collaborative efforts, it’s about educating patients, helping them help their doctors, and to live better with the disease and have a better quality of life.”&nbsp;SES will be running more industry-directed webinars soon; please look out for future registration forms.If you are interested in speaking to SES about supporting our educational initiatives and incorporating the patient voice, please get in touch: <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">partnerships@scientificeducationsupport.com</a>&nbsp;

SES Jun23 Webupdate_webiniar.png

SES webinar recap 

IME hub innovations: User accounts and personalized education journeys &nbsp;Here at SES, one of our priorities is to constantly refine and develop our offering – for both users and supporters.&nbsp;Our most recent updates across the portfolio of platforms included the introduction of translation functionality across our education, meaning we can supply content in over 100 languages, permitting truly global reach, as well as the introduction of the hub drug updates page, which allows users to access the latest drug and trial news as it is reported from our Twitter accounts.&nbsp;We are very excited to announce the introduction of user accounts across the suite of platforms, with the <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank">Lymphoma Hub</a> being the first to see the roll-out later in Q4 of 2023.&nbsp;This innovation will ensure that the content can remain open-access and free but, for those who want it, users can start building learning journeys and bookmark and save articles of interest – enabling the creation of a personalized journey.&nbsp;Knowing more about the user’s interests will allow us to suggest further content to develop their learning journey. Importantly for us, it will provide essential profiles on our audience and what they need, allowing us to offer higher levels of learning outcomes as we will be able to link learning resources, reinforce education, and track outcomes.&nbsp;For more information around how your organization can support targeted education in Lymphoma and CLL, please contact:partnerships@scientificeducationsupport.com.&nbsp;&nbsp;EULAR, ERA, &amp; WCD – The SES Immunology Hubs go on their travels! &nbsp;Our global, open-access online platforms provide balanced, credible, and up-to-date medical education. In 2022, we successfully launched our first platforms within the immunology space: the <a href="https://psoriasis-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Psoriasis and Psoriatic Arthritis Hub</a> and the <a href="https://lupushub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lupus Hub</a>.&nbsp;A vital element of comprehensive global IME delivery is our investment in international congress coverage.&nbsp;&nbsp;Together with our global steering committees, we identify key congresses that we would like to cover over a 12-month period. At the congresses, our medical writers attend as many sessions as possible and post live coverage to our social media feeds, sharing key data and news with our followers as soon as it is released. We provide congress digests, key updates, and live coverage over social media – ensuring we disseminate learning with our HCP communities, closing the learning gap for those who are not able to attend themselves.&nbsp;We are frequently the top influencer at congresses we attend for our current hubs. Being a top influencer means that of all the tweets surrounding the conference, ours are the ones with the most interaction. In this way, we are ensuring education is provided to the masses through our targeted tweets.&nbsp;This summer, our immunology hubs attended the 2023 European Alliance of Associations for Rheumatology (EULAR) Congress in Milan, Italy. During May 31 – June 3, over 12,000 delegates from around 125 countries met to share the latest scientific breakthroughs in clinical, translational, and basic sciences to guide treatment in rheumatic and musculoskeletal diseases.&nbsp;The dedicated coverage by our scientific teams secured an average of 1,989 impressions per post, with an engagement of 9.5%. Industry standards consider 0.5% to be a good engagement rate for Twitter, with anything above 1% seen as great – so to be hitting these metrics at such an early point in the platforms’ journeys is a testament to the quality and relevance of the content provided by the platforms.&nbsp;It was a quick turnaround for the <a href="https://lupushub.com/" rel="noopener noreferrer" target="_blank">Lupus Hub</a> team to get back out to Milan for the 60th Annual European Renal Association (ERA) congress, June 15–18, 2023. With over 9,000 registrants from 123 countries, ERA showcased key lupus updates for coverage on the hub and boasted a daily Twitter audience of 16,000 HCPs. Securing up to 1,481 impressions per post, with an engagement rate of 7.3%, this was a key audience for the team to reach through the hub’s activities.&nbsp;The immunology team rounded off the summer with a longer flight to cover the key sessions at the World Congress of Dermatology (WCD), July 3–8, 2023, in Singapore.&nbsp;The congress, which runs every 4 years, aims to improve cooperation across geographic, political, and economic borders and improve skin health for all. The broad program covers clinical areas, community engagement, and research.&nbsp;Representatives from the SES partnerships team were delighted to attend in support of the scientific team to meet with key stakeholders in psoriasis, with a view to discuss the development and growth of the platform – both in terms of educational priorities and supporters. With over 12,000 attendees, there were lots of conversations to be had!&nbsp;For more information about our congress coverage plans or how you can support education in immunology, please contact our partnerships team.&nbsp;Partnerships@scientificeducationsupport.com

SES Aug23 Webupdate image_UserAccounts.png

Partnerships update, August 2023

As we go further into Q4 and a busy congress season across our education platforms, this is a perfect time to reflect on the value of our continued coverage of scientific congresses.&nbsp;&nbsp;Our dedicated IME (Independent Medical Education) platforms have two key aims. Firstly, educating healthcare professionals on targeted learning gaps identified through robust needs assessments directed by our global steering committees. Secondly, we endeavor to keep healthcare professionals abreast of the latest data across their indication.&nbsp;&nbsp;To ensure we are keeping up with the latest science, we attend key congresses and design live micro-learning social media campaigns on the highlights and key educational messages. At the congresses, our medical writers attend as many sessions as possible and post live coverage to our social media feeds, sharing key data and news with our followers.&nbsp;&nbsp;We are frequently the top influencer at the congresses we attend. In this way, we ensure up-to-date medical education is provided to the masses.&nbsp;Among other activities, September included coverage of the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting in Houston. With an attendance of over 3,500 dedicated healthcare professionals, including physicians, nurses, and specialists, this year's symposium aimed to explore the latest advances in the pathophysiology and therapy of hematologic malignancies. An extensive range of topics were covered, including leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, related malignancies, and exciting developments in cellular therapy.&nbsp;Below are some of the highlights of SOHO 2023 which were covered on our hubs:&nbsp;<ul><li>Lymphoma Hub: <a href="https://lymphomahub.com/medical-information/how-can-we-improve-care-for-elderly-patients-with-hl" rel="noopener noreferrer" target="_blank" style="background-color: var(--clrFieldRangeBackground, #e1e3e6); color: var(--clrFieldRange, #000000);">How can we improve care for elderly patients with </a>HL?&nbsp;</li><li>Multiple Myeloma Hub: <a href="https://multiplemyelomahub.com/medical-information/outcomes-in-patients-with-mm-achieving-mrd-negativity-after-treatment-with-cilta-cel-cartitude-1" rel="noopener noreferrer" target="_blank" style="background-color: var(--clrFieldRangeBackground, #e1e3e6); color: var(--clrFieldRange, #000000);">Outcomes in patients with MM achieving MRD negativity after treatment with cilta-cel: CARTITUDE-1</a>&nbsp;</li><li>MPN Hub: <a href="https://mpn-hub.com/medical-information/novel-non-jak-inhibitors-for-mf-updates-from-soho-2023" rel="noopener noreferrer" target="_blank" style="background-color: var(--clrFieldRangeBackground, #e1e3e6); color: var(--clrFieldRange, #000000);">Novel non-JAK inhibitors for MF: Updates from SOHO 2023</a>&nbsp;</li><li>MPN Hub: <a href="https://mpn-hub.com/medical-information/treatment-options-in-patients-with-myelofibrosis" rel="noopener noreferrer" target="_blank" style="background-color: var(--clrFieldRangeBackground, #e1e3e6); color: var(--clrFieldRange, #000000);">Treatment options in patients with myelofibrosis</a>&nbsp;</li></ul>The SES team will be out in full force until the end of 2023, we would be delighted to meet with you, share our work, and understand more about yours—please let us know if you would like to meet.&nbsp;&nbsp;<ul><li>ESH 6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment&nbsp;</li><li>15th International Hybrid Congress on Myeloproliferative Neoplasms&nbsp;</li><li>EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms&nbsp;</li><li>American College of Rheumatology (ACR) Annual Meeting (ACR Convergence)&nbsp;</li><li>65th ASH Annual Meeting &amp; Exposition&nbsp;</li></ul>Contact the team for more information: <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="background-color: var(--clrFieldRangeBackground, #e1e3e6); color: var(--clrFieldRange, #000000);">partnerships@scientificeducationsupport.com</a>&nbsp;&nbsp;&nbsp;

SES Partnerships updates Oct234_webupdate_2.png

The value of congress attendance for the Scientific Education Support hubs

Recently, SES ran its first ever webinar, spotlighting the importance of incorporating the patient voice in medical education; we kicked off the webinar with an <a href="https://youtu.be/xhJ56VT8wlI?si=xGTSG2pOxR80ylww" rel="noopener noreferrer" target="_blank" style="color: var(--clrFieldRange, #000000); background-color: var(--clrFieldRangeBackground, #e1e3e6);">intro</a> on the topic from our Acting Managing Director, Mia Hill.&nbsp;As eloquently put by the Father of Modern Medicine, William Osler: “to study the phenomena of disease without books is to sail an uncharted sea, while to study books without patients is not to go to sea at all.” Osler, who paved the way to bedside clinical training, was a firm believer in patient-guided medical education, aligning with our mission at SES.&nbsp;Integrating the patient perspective into Independent Medical Education (IME) is imperative to the exceptional education we provide. Our HCP users are able to learn through replica case studies, clinical trial clubs, and interactive modules formulated with patient experience and real-world scenarios. Through these learning formats, physicians can develop their clinical practice and diagnosis criteria, gaining insights from all aspects of disease evolution.&nbsp;In this educational 45-minute session, we had the privilege of hearing from key individuals in the world of medical education:&nbsp;Carl Harrington, a patient and former president and chairman of the board of IWMF, discussed the importance of patient advocacy in supporting all patients with Waldenstrom’s macroglobulinemia (WM) and shared some insights into collaborating with SES—watch <a href="https://www.youtube.com/watch?v=Lp3gYJ3Df4I" rel="noopener noreferrer" target="_blank" style="color: var(--clrFieldRange, #000000); background-color: var(--clrFieldRangeBackground, #e1e3e6);">here</a>. Our collaboration brings empowerment to patients struggling with undiagnosed WM and significant disease awareness to HCPs globally.&nbsp;Lyndsy Ambler, a patient representative on the Lupus Hub Steering Committee, championed a holistic approach to IME, emphasizing that <a href="https://www.youtube.com/watch?v=N9OVjtopJ2Q" rel="noopener noreferrer" target="_blank" style="color: windowtext;">patients</a> possess unique insights into the daily realities of living with their conditions, revealing key <a href="https://www.youtube.com/watch?v=oCFXorm64Eo" rel="noopener noreferrer" target="_blank" style="color: windowtext;">educational gaps</a> in lupus. We have been <a href="https://www.youtube.com/watch?v=JzY5bLdNwfw" rel="noopener noreferrer" target="_blank" style="color: windowtext;">collaborating</a> with Ambler to close these gaps in the field and improve patient care.&nbsp;Ricard Cervera, Lupus Hub Chair and head of the Department of Autoimmune Diseases at Hospital Clinic, Barcelona, underlined the importance of <a href="https://www.youtube.com/watch?v=7l6ROx9PfyI" rel="noopener noreferrer" target="_blank" style="color: windowtext;">incorporating the patient voice</a> in lupus treatment, sharing invaluable insights into the different manifestations experienced by patients. Cervera described his experience of ﷟HYPERLINK "https://www.youtube.com/watch?v=J7R_ALPkg_g"working with SES to improve patient lives and educate HCPs on the latest treatment options, as well as the importance&nbsp;that provides practitioners with the right tools to make a lLupus diagnosis.of <a href="https://www.youtube.com/watch?v=X5ryqyQSdVk" rel="noopener noreferrer" target="_blank" style="color: windowtext;">education</a> that provides practitioners with the right tools to make a lupus diagnosis.&nbsp;Cheryl Petruk, a member of the MPN–PAG Collaborative Steering Committee who was the primary caregiver for her husband battling MPN, emphasized the vital role of <a href="https://www.youtube.com/watch?v=jiwjxNjyTWc" rel="noopener noreferrer" target="_blank" style="color: windowtext;">patient inclusion</a> in all communications. Petruk shed light on the importance of the effective education of <a href="https://www.youtube.com/watch?v=HD5Zh0ugm98" rel="noopener noreferrer" target="_blank" style="color: windowtext;">patients</a> on their disease in order to provide a sense of power and control.&nbsp;During the webinar, the renowned panelists highlighted the practical aspects of translating these ideas into action. They also discussed examples of SES actively supporting these initiatives through educational programs which focus on providing up-to-date knowledge to HCPs and patients alike, thereby bridging the gap between treatment and care.&nbsp;We invite you to watch the full webinar below:&nbsp;<a href="https://www.youtube.com/watch?v=QipnmrMzQxA" rel="noopener noreferrer" target="_blank" style="color: var(--clrFieldRange, #000000); background-color: var(--clrFieldRangeBackground, #e1e3e6);">https://www.youtube.com/watch?v=QipnmrMzQxA</a>&nbsp;&nbsp;

SES Partnerships updates Oct236_webupdate_3.png

SES Webinar: Incorporating the patient voice in medical education – hear from our expert speakers

July has provided an opportunity for the Partnerships team to take stock of the amazing innovations our platforms have been able to deliver due to our supporters. As we move towards a well-deserved summer break, we want to remind our followers of some of the key features that have been added to our platforms throughout the first half of 2022.&nbsp;<h2>Google Translate&nbsp;&nbsp;</h2>Our platforms have a global audience, with our content reaching over 161 countries. It has become crucial that access to our wide range of content is made as broad as possible; therefore, the introduction of Google Translate has advanced this. Google Translate enables content to be translated to over 100 languages, including Punjabi, Japanese, and Arabic.&nbsp;<h2>Pre- and post-learning tests&nbsp;&nbsp;</h2>Our quiz questions are designed to aid the learning journey in accordance with our learning objectives and are intended as a fun challenge for readers, providing them with the opportunity to test their knowledge, improve on their pre-content quiz score, and compare themselves to the average score of their colleagues. The quizzes also allow us to measure the effectiveness of our education. This is critical in enabling us to observe any persisting gaps/educational needs and to continually monitor our educational design to ensure it meets the needs of our readers optimally.&nbsp;<h2>Drug update Twitter feed&nbsp;</h2>Our hub Twitter channels are a fantastic source of information and updates for the community. We are now pleased to be able to host our medical update Twitter feeds directly on the hub websites. The drug update tabs can be viewed for the latest bite-sized news in clinical developments and regulatory updates.&nbsp;&nbsp;&nbsp;----------------------------------------------------------------------------------------------------------------------------------&nbsp;<h2>A NUMBER OF EXCITING INITIATIVES ARE COMING SOON&nbsp;</h2><h3>World ALL Day (September 20, 2022): Know your subtype&nbsp;</h3>Through a successful collaboration, <a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank">Know ALL</a>, SES, and the <a href="https://acuteleuk.org/" rel="noopener noreferrer" target="_blank">Acute Leukemia Advocates Network (ALAN) </a>are working together to host an inaugural World ALL Day. This event will be held on September 20, 2022, and as the first event of its kind, its aim is to mobilize patients, carers, and HCPs and increase the awareness of acute lymphoblastic leukemia (ALL).&nbsp;The “Know your subtype” campaign delivered throughout the day will encourage patients to share their subtype and share their story in order to help increase knowledge of different ALL subtypes and how they are classified among the community.&nbsp;&nbsp;If you would like more information on how to support World ALL Day or the Know ALL initiative, please contact Geoff.Jones@scientificeducationsupport.com.&nbsp;<h3>MDS International Guidelines&nbsp;</h3>The MDS International Guidelines project is a global project that is being developed with the mission of raising the standards of disease management in myelodysplastic syndromes (MDS) globally through the development of contemporary and practical MDS treatment guidelines.&nbsp;Hosted on a web-based, multichannel, open-access platform, the guidelines will be available in a responsive format suitable for phones, tablets, and computers. It’s hoped the mobile responsiveness can be utilized to encourage daily use within clinical practice. We are seeking industry support to ensure this project delivers upon its full potential and generates a comprehensive set of clinically advocated guidelines for use in the frontline hematology setting.&nbsp;Please contact sarah.rustin@scientificeducationsupport.com for further information on how to get involved.&nbsp;&nbsp;<h3>SES at the International Myeloma Society (August 25–27)&nbsp;&nbsp;</h3>Partnership Director, Ken Zangina, alongside Indication Lead, Marta Llobet, will be attending the International Myeloma Society congress in Los Angeles on August 25–27, where they are looking forward to meeting key industry stakeholders within multiple myeloma. They also look forward to meeting with existing supporters and potential partners of the Multiple Myeloma Hub.&nbsp;To arrange a meeting and to receive a Multiple Myeloma Hub update, please contact ken.zangina@scientificeducationsupport.com.&nbsp;&nbsp;--------------------------------------------------------------------------------------------------------------------------------------&nbsp;<h2>SUPPORTER UPDATES&nbsp;</h2><h3>MPN Hub&nbsp;&nbsp;</h3>We are delighted to confirm that Sierra Oncology will be continuing its support of the <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank">MPN Hub</a>. Through becoming a Bronze supporter, Sierra Oncology’s support will contribute towards enabling growth of the MPN Hub, which will continue to highlight the breadth of treatment options available for patients with myelofibrosis and other types of MPN.&nbsp;&nbsp;<h3>ALL Hub&nbsp;</h3>We are delighted to announce that Amgen will be continuing to support the <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank">ALL Hub</a> as a Silver supporter. As a leading stakeholder in the care of patients with ALL, we are pleased Amgen have reaffirmed their support for the platform.&nbsp;&nbsp;--------------------------------------------------------------------------------------------------------------------------------------&nbsp;<h2>BESPOKE EDUCATIONAL OPPORTUNITIES&nbsp;</h2>We are seeking grants from our existing and new industry partners to support the delivery of new and innovative educational learning interventions for the hematology community. Through the delivery of these bespoke initiatives across our established learning platforms, we hope to demonstrate advanced levels of learning in targeted areas of unmet needs relevant to HCPs.&nbsp;&nbsp;CAR T-cell therapy (a multi-platform webinar series from the <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank">Lymphoma Hub</a>, <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank">Multiple Myeloma Hub</a>, and <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank">ALL Hub</a>)&nbsp;&nbsp;In a first for our hematology hubs, this webinar series will address unmet educational needs pertaining to the growing scope of CAR-T cell therapies across the hematology indications. With consideration of the complex treatment journey, from the initial consultation through to transition of care, this project aims to support HCPs involved in this new and evolving treatment area, enabling them to make optimal treatment choices for their patients. Leveraging the remarkable reach of three relevant hub platforms, the content will also remain on the platforms as a valuable source of enduring content.&nbsp;&nbsp;<h3>Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis (a clinical trial club)&nbsp;&nbsp;</h3>Following the success of our first clinical trial club webinar, which focussed on navtemadlin, we hope to provide further webinars within this series to highlight other novel agents for the treatment of advanced myelofibrosis.&nbsp;A clinical trial club is a live webinar where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support HCPs in understanding what the latest news means for clinical practice. They offer the ideal solution to address the key learning gap of suboptimal knowledge of novel therapeutic targets in MPN.&nbsp;<h3>Sequencing of therapies in acute lymphoblastic leukemia (a case-based symposium)&nbsp;</h3>This case-based symposium will discuss the issues associated with the sequencing of therapies for B-cell ALL. A panel of selected ALL Hub key opinion leaders will discuss cases related to this subtype of the disease.Pre- and post-case discussions will help develop the viewers’ understanding of the recommended treatment algorithm in these cases, and viewer interactivity with the panel will help raise confidence and competence in their management of the disease. We are seeking support from industry stakeholders to enable the delivery of this learning initiative.&nbsp;&nbsp;If you would like to learn more about supporting these educational initiatives, please contact the Partnerships team at partnerships@scientificeducationsupport.com.&nbsp;

July 2022 update from the partnership team at Scientific Education Support.

SES July22 WebUpdateHeader_0.1_PartnershipsUpdate.png

Partnerships update-July 2022 

In May, <a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank">Know AML</a> launched a patient survey in collaboration with <a href="http://www.haymarketmedicaleducation.com/" rel="noopener noreferrer" target="_blank">Haymarket Medical Education</a> (HME). The survey aimed to gain insights on the patient perspective regarding maintenance therapy and alternative treatment options to allogeneic hematopoietic stem cell transplantation, incorporate the patient voice into care plans, and raise awareness of the healthcare disparities in AML.&nbsp;The survey was disseminated via the Know AML global network and patient advisory group, and across the Know AML social media channels and website.&nbsp;&nbsp;&nbsp;Through partnership with Know AML, HME will be using the results of the survey to incorporate the patient voice and develop a truly patient-centric curriculum.&nbsp;&nbsp;We are looking forward to sharing the results from the survey soon!&nbsp;

In May, Know AML launched a patient survey in collaboration with Haymarket Medical Education (HME)

SES July22 Newsletter_0.2_PatientSurvey.png

Know AML Patient Survey Update

Across our IME hubs, we recently hosted a number of expert discussions with steering committee members, covering some of the current key topics in hematology.

Expert Discussions.png

Expert Discussions In Hematology

Clinical trials are the foundation for the development of treatments across the world; however, there are numerous elements that make understanding the key outcomes of trials and the implementation of a successful trial into clinical practice challenging for healthcare professionals (HCPs). Questions regarding the location, referral processes, patient eligibility, trial requirements, accessibility, and risks are among the recurring concerns voiced by HCPs and candidates.&nbsp;&nbsp;Here at SES, we can provide multi-supported, accredited clinical trial club webinars across our hubs, with the intention to demystify the complexities of clinical trials. The sessions offer the opportunity for hub users to interact with our world-renowned steering committee and hear their expert opinions on the latest data and its impact on clinical practice.&nbsp;With a dedicated engagement campaign to maximize HCP attendance, these clinical trials clubs increase knowledge and awareness of the trials covered, and facilitate learning to ensure HCPs become more informed around the suitability of a trial for their patients, as well as the key outcomes data and how this will impact clinical practice when the drug is launched.&nbsp;&nbsp;During the session, a guest author/lead investigator presents the key highlights of a publication/clinical trial and the expert panel discuss what this latest update means for the future of clinical practice. The session is recorded and hosted as an enduring piece of education on the hub to further enhance reach and key educational snippets are also circulated on the hub’s social media channels to create impactful and wide-reaching microlearning.&nbsp;&nbsp;Please contact us if you would like to learn more about the different clinical trials clubs we can offer across our indications and how we can showcase your work.&nbsp;&nbsp;📧Partnerships@scientificeducationsupport.comEmma WilliamsScientific Education SupportDigital innovation&nbsp;On a biannual basis, our engagement team delivers reports for our supporters to showcase the latest hub outcomes. These reports provide valuable insights, such as user metrics, regional breakdowns, and which articles have been published that are relevant to the supporter. The reports also provide updates on the outcomes from unmet needs submissions that have been provided by our supporters.&nbsp;Following recent digital innovation, we can now share these reports via a link that can be circulated internally. The visuals are designed for easy viewing in presenter mode on large screens or personal computers and relevant links are provided to signpost supporters to insightful and useful content.&nbsp; <img src="https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/25712d4b43d3a7c8bb8b30088a4b2ff3.png" alt="Picture1.png"><img src="https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/4e8418de62c2ac0e4d7082369a2d3a05.png" alt="Picture2.png"><img src="https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/52db839dc03ac27bd7347cf06cdbcfc1.png" alt="Picture3.png">Geoffrey JonesScientific Education Support

SES March23 WebUpdate_2.png

Partnerships Update

SES success as EHA2023&nbsp;EHA2023 in Frankfurt, Germany was an incredible success for us personally at SES! On the Friday evening and with a packed auditorium, we delivered a live, hybrid Lymphoma Hub and Multiple Myeloma Hub symposium on: The ins and outs of CAR T cells in the real world.&nbsp;The success of this event cemented the fact that IME symposia attract HCPs in droves!&nbsp;&nbsp;We are now gearing up to upscale this offering to our industry supporters; from the smaller congresses to the biggest, we have the ability to develop and implement truly thought-provoking content that addresses clinical gaps. Our use of pre- and post-test questioning allows us to measure the learning outcomes delivered. Our recent symposium saw participants increase their knowledge by an average of 21% on the topic of metabolic tumor volume and 89% of respondents felt they could use what they had heard in the symposium in their clinical practice.&nbsp;&nbsp;&nbsp;&nbsp;Please get in touch with the partnerships team to find out more about how you can support: <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">partnerships@scientificeducationsupport.com</a> SES and FOCIS: Working together to deliver IME in immune-mediated diseases&nbsp;&nbsp;SES is an independent medical education agency with a strong heritage in hematology and a growing presence in immunology.&nbsp;Our global, open-access online platforms provide balanced, credible, and up-to-date medical education in their respective indications. In 2022, we successfully launched our first platforms within the immunology space; first the <a href="https://psoriasis-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Psoriasis and Psoriatic Arthritis Hub</a>, followed by the <a href="https://lupushub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lupus Hub</a>.&nbsp;&nbsp;Across our portfolio of IME platforms, we are reaching over 244,000 unique users across 190 countries annually. In 2023, we plan to launch a dedicated IBD Hub, which will be the first of its kind in the IBD field, with another hub focussing on multiple sclerosis to follow.&nbsp;&nbsp;We could not do this without our vital partnerships with international societies and patient groups from across the world, which allow us to create innovative educational initiatives that give rise to empowered communities, stronger networks, and greater collaboration opportunities.&nbsp;Guiding our journey into the immunology space via the <a href="https://lupushub.com/%22%20/h%20HYPERLINK%20%22https://lupushub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">Lupus Hub</a> has been our overarching partnership with the <a href="https://www.focisnet.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Federation of Clinical Immunology Societies (FOCIS)</a>. Through FOCIS, researchers and clinicians share knowledge across traditional disease borders and identify commonalities between treatments and therapies that are life-changing for those impacted by immune-mediated diseases.&nbsp;&nbsp;FOCIS has 62 member societies, representing roughly 65,000 clinician scientists, which is critical in ensuring we can share education as far as possible and reach communities that we might not otherwise be able to.&nbsp;&nbsp;Part of our support was to attend the <a href="https://www.focisnet.org/meetings/focis-2023/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">23rd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2023)</a>, which took place on June 20–23, 2023, at the Boston Marriott Copley Place, Boston, US.&nbsp;The SES team were delighted to connect with the FOCIS community to share details of our collaboration in delivering IME in lupus, IBD, and cancer immunotherapy.&nbsp;&nbsp;If you would like to know more about our work in these areas, please email us at partnerships@scientificeducationsupport.com&nbsp;

MicrosoftTeams-image (87).png

Success at EHA and FOCIS 2023

Scientific Education Support provides secretariat support for the Global Cholangiocarcinoma Alliance.This February, the collective voice of the <a href="https://globalccaalliance.com/en" rel="noopener noreferrer" target="_blank"> Global Cholangiocarcinoma Alliance</a> came together to mark <a href="https://globalccaalliance.com/en/world-cca-day" rel="noopener noreferrer" target="_blank"> World Cholangiocarcinoma Day with a campaign to raise awareness and support for cholangiocarcinoma (CCA) called “See CCA.”</a> The GCA has united to establish a global community in CCA through international collaborations, and it works towards improving the future for patients with CCA across the globe.​&nbsp;CCA, also known as bile duct cancer, is a cancer with a high mortality rate. Although it is considered rare, the worldwide incidence of this devastating cancer is increasing. The epidemiology of the disease varies between regions, with risk factors well defined in some areas and poorly in others.​&nbsp;As part of our campaign for World CCA Day, we launched a wide range of materials that can be found and downloaded here on the <a href="https://globalccaalliance.com/en/world-cca-day" rel="noopener noreferrer" target="_blank"> GCA website</a> . All were made available in multiple formats, including editable, to ensure easy translations and global inclusivity!​ We urged everyone to get involved online and offline and encouraged colleagues and friends to do so too to show support and raise awareness.&nbsp;&nbsp;On February 11–13, the Twitter hashtags #WorldCCADay and #SeeCCA saw over 9,000 impressions and 1,500 engagements, including retweets, likes, and mentions. Across Facebook and Instagram, we increased our page likes, drove upwards of 450 page views and 175 profile visits, and saw continuous engagement and interactions throughout.&nbsp;Our integrated campaign running for the month of February also includes the promotion of a series of patient support animations covering a variety of topics, including the causes, diagnosis, and treatment of CCA. These can all be found here on the <a href="https://globalccaalliance.com/en/cca-facts" rel="noopener noreferrer" target="_blank"> GCA website</a> , and initial results show high levels of engagement, particularly on Facebook. Our campaign will run until the end of February to encourage as many people as possible to get involved and raise awareness of CCA for World CCA Day and beyond.&nbsp;You can support the goals of the GCA further by joining 1,127 people who have already <a href="https://globalccaalliance.com/en/get-involved/the-pledge" rel="noopener noreferrer" target="_blank"> signed the pledge to support the CCA community</a> to raise awareness globally. We use these pledges to continue to build a network of informed supporters who will strengthen and expand our reach in establishing a global voice in CCA and ensure our vision becomes a reality.&nbsp;If you would like any more information about the campaign, please do not hesitate to get in touch via <a href="mailto:SESGCA@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank"> SESGCA@scientificeducationsupport.com</a> and follow our social channels.&nbsp;&nbsp;Twitter: <a href="https://twitter.com/CCA_Alliance" rel="noopener noreferrer" target="_blank"> @CCA_Alliance</a>Facebook: <a href="https://www.facebook.com/globalCCAalliance" rel="noopener noreferrer" target="_blank"> @globalCCAalliance</a>World CCA Day Facebook: <a href="https://www.facebook.com/worldccaday/" rel="noopener noreferrer" target="_blank"> @worldccaday</a>World CCA Day Twitter: <a href="https://twitter.com/WorldCCADay" rel="noopener noreferrer" target="_blank"> @WorldCCADay</a>World CCA Day Instagram: <a href="https://www.instagram.com/worldccaday/" rel="noopener noreferrer" target="_blank"> @worldccaday</a>

This February, the collective voice of the  Global Cholangiocarcinoma Alliance came together to mark  World Cholangiocarcinoma Day with a campaign to raise awareness and support for cholangiocarcinoma (CCA) called “See CCA.”

5ef3f703b2348afcf63257ced505d823.jpeg

The Global Cholangiocarcinoma Alliance (GCA) – World Cholangiocarcinoma Day- 12 February 2022 and beyond

Scientific Education Support (SES) provides open access, science-driven, independent, global education initiatives through our hubs for hematologic malignancies and rheumatic disorders across all phases of the product life cycle (conception, preclinical and clinical product development, approval, and commercialization). Starting with robust needs assessments, in collaboration with expert steering committees, our education solutions increase knowledge and enhance competence among healthcare professionals (HCPs) by improving access to balanced, credible, and up-to-date medical education where there is an unmet need.&nbsp;&nbsp;We achieve our educational objectives through various formats, including the following:&nbsp;<ul><li><a href="https://lymphoblastic-hub.com/medical-information/phase-ii-trial-results-of-inotuzumab-ozogamicin-in-older-patients-with-de-novo-b-all-gmall-initial1-trial" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Clinical trial updates</a>, including on new studies, results, halted activity, or completion&nbsp;</li><li><a href="https://lymphomahub.com/medical-information/cart-2023" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Congress updates</a> from educational sessions, poster sessions, speakers, and key opinion leaders&nbsp;</li><li><a href="https://mpn-hub.com/medical-information/editorial-theme-meta-analysis-of-the-effectiveness-of-anticoagulant-therapy-in-patients-with-splanchnic-vein-thrombosis" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Educational articles</a> on specific topics or themes relevant to the treatment of patients&nbsp;</li><li><a href="https://mds-hub.com/medical-information/challenges-of-measuring-overall-survival-in-elderly-patients-with-mds" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Expert discussions</a> between two or more key opinion leaders on a specific topic or clinical advancement&nbsp;</li><li><a href="https://gvhdhub.com/medical-information/itacitinib-and-corticosteroids-for-chronic-gvhd" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Expert opinions</a> on specific topics, advances, clinical trials, or congress posters/oral sessions&nbsp;</li><li><a href="https://lymphomahub.com/medical-information/resource-stratified-guidelines-for-the-management-of-classical-hodgkin-lymphoma" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Summaries of new or updated guidelines</a> to help inform clinical practice&nbsp;</li><li><a href="https://lymphoblastic-hub.com/medical-information/ash-2022-abstracts-what-s-hot-in-acute-lymphoblastic-leukemia" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Top abstracts lists</a> to aid congress planning and provide readers with a summary of congress highlights&nbsp;</li><li><a href="https://gvhdhub.com/medical-information/case-study-51-year-old-with-chronic-gvhd-with-no-improvement-after-a-week-on-prednisone" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">"How I treat"</a> patient cases, with contributions from key opinion leaders&nbsp;</li><li><a href="https://aml-hub.com/drug-updates" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Regulatory updates</a>, including approvals, priority reviews, fast-track designations, and orphan designations&nbsp;</li><li><a href="https://lymphomahub.com/drug-updates" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">News updates</a> on general therapy area advancements and breakthroughs&nbsp;</li><li><a href="https://lymphomahub.com/medical-information/talking-to-your-patients-with-waldenstrom-macroglobulinemia" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Patient perspectives</a> on a scientific topic or advancement for the benefit of HCPs&nbsp;</li><li><a href="https://lymphoblastic-hub.com/medical-information/philadelphia-negative-all-a-summary-of-hot-topics-presented-at-ash-2022" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Practice-changing abstract summaries</a> to ensure HCPs understand the upcoming changes in treatment paradigms&nbsp;&nbsp;</li><li><a href="https://lymphomahub.com/medical-information/irene-g-a-prospective-rct-of-nutritional-support-following-allo-hsct" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Summaries</a> of important manuscripts and must-read publications&nbsp;</li></ul>We effectively communicate scientific messages using compelling designs and infographics, and we continuously stay up to date on new breakthroughs by monitoring activity at scientific conferences and recent literature in the field.&nbsp;To appeal to a range of learning styles, we publish multi-format content, such as:&nbsp;<ul><li><a href="https://lymphomahub.com/medical-information/visual-abstract-or-phase-ii-trial-of-glofitamab-following-obinutuzumab-pretreatment-in-patients-with-rr-dlbcl" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Visual abstracts</a>: Condensed infographic summaries that provide bite-sized education that is easily integrated into learners’ daily routines&nbsp;</li><li><a href="https://gvhdhub.com/medical-information/orca-t-in-patients-undergoing-allo-hsct-for-hematologic-malignancies" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Short highlight articles</a>: Digestible, quick reads that keep learners up to date with the latest news and regulatory updates&nbsp;</li><li><a href="https://lymphomahub.com/medical-information/treatment-landscape-for-rr-wm" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">In-depth articles:</a> Longer reads that provide learners with greater detail and context on the evolving therapeutic landscape&nbsp;</li><li><a href="https://multiplemyelomahub.com/medical-information/why-should-frailty-be-considered-a-dynamic-factor-in-mm-and-when-should-it-be-assessed" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Video interviews</a>: Audio-visual, flexible and self-paced; an opportunity for learners to connect with experts and benefit from their insights&nbsp;</li><li><a href="https://lupushub.com/medical-information/what-do-hcps-need-to-know-about-ln-and-the-prevention-of-progression-to-esrd" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Podcasts</a>: Portable, convenient, and available on popular platforms (Amazon Music, Apple, Spotify, YouTube, Google Podcasts, Deezer, Flash Briefing, iHeartRadio, Stitcher, and TuneIn)&nbsp;</li><li><a href="https://gvhdhub.com/medical-information/tct-2023" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Social media:</a> Key updates, animations, and visual abstracts, which provide bite-sized education that is easily integrated into learners’ daily routines&nbsp;</li></ul>We also offer a variety of bespoke educational offerings through our hubs, including:&nbsp;<ul><li>Case study clubs: Live webinars of ~30 minutes on a case study, with recordings that are repurposed as videos and podcasts on our hubs&nbsp;</li><li><a href="https://mpn-hub.com/medical-information/clinical-trial-club-navtemadlin-vs-best-available-therapy-in-relapsed-or-refractory-myelofibrosis" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Clinical trial clubs</a>: Live webinars of ~30 minutes on a clinical trial, which provide outcomes data up to Moore's Level 5 and recordings that are repurposed as videos and podcasts&nbsp;</li><li>Interactive cases: Short, interactive eLearning modules that replicate real-world scenarios and provide a safe place for HCPs to practice treatment decisions&nbsp;</li><li><a href="https://gvhdhub.com/medical-information/key-considerations-for-the-use-of-ecp-in-gvhd" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Symposia</a>: Standalone or congress-associated events, which can be easily adapted to the online space, allowing a large audience to receive important data either live or as post-event recordings&nbsp;</li></ul>In 2022 we had 248,671 unique HCPs visit our hubs. On average, our hubs are achieving a satisfaction score of 4.6/5 among learners and is increasing HCP knowledge by 27%. Through the delivery of content that HCPs truly need, via interactive and engaging formats we ensure impactful education reaches a large audience and makes a difference.&nbsp;

SES Apr23 Webupdate image.png

An overview of hub activities 

SES Aug22 WebUpdates_0.1_HubInnovation.png

New IME hubs digital innovation: Congress Twitter feed section update 

<h2>Summer recap&nbsp;</h2>After a very warm summer, we are excitedly finalizing our plans for the last few months of 2022 and&nbsp;turning towards full planning mode for 2023. We hope to share some key updates with you in the coming months.&nbsp;Supporters of both our IME and patient platforms will have also received the most up-to-date metrics from Q2 2022. We saw fantastic metrics across the board in Q2 and with a particular look at all of our IME platforms we can draw out some key highlights, including:&nbsp;<ul><li>26 video interviews&nbsp;</li><li>92 published articles&nbsp;</li><li>4,464 Twitter link clicks&nbsp;</li><li>1,055,677 Twitter impressions&nbsp;</li><li>55,808 website users&nbsp;</li></ul>We would be delighted to share more information regarding our outcomes; if you are not yet a supporter of our platforms and would like some further insights, such as participation metrics, social media activity, YouTube and podcast channel metrics, and poll results, please contact the Partnerships Team at <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">partnerships@scientificeducationsupport.com</a>.&nbsp;<h2>A number of exciting initiatives are coming soon throughout September&nbsp;</h2><h3><a href="https://know-alleukemia.com/get-involved/world-awareness-day" rel="noopener noreferrer" target="_blank">World ALL Day (September 20, 2022): Know your subtype &nbsp;</a></h3>Through a successful collaboration, <a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank">Know ALL</a>, SES, and the <a href="https://acuteleuk.org/" rel="noopener noreferrer" target="_blank">Acute Leukemia Advocates Network (ALAN) </a>are working together to host the inaugural <a href="https://know-alleukemia.com/get-involved/world-awareness-day" rel="noopener noreferrer" target="_blank">World ALL Day</a>. This event will be held on September 20, 2022, and as the first event of its kind, its aim is to mobilize patients, carers, and HCPs in increasing the awareness of acute lymphoblastic leukemia (ALL).&nbsp;The “know your subtype” campaign delivered throughout the day will encourage patients to share their subtype and share their story in order to increase knowledge of different ALL subtypes and how they are classified among the community.&nbsp;If you would like more information on how to support World ALL Day or the Know ALL initiative, please contact <a href="mailto:Geoff.Jones@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Geoff.Jones@scientificeducationsupport.com</a>.&nbsp;<h3>MDS International Guidelines&nbsp;&nbsp;</h3>The MDS International Guidelines project is a global project that is being developed with the mission of raising the standards of disease management in myelodysplastic syndromes (MDS) globally through the development of contemporary and practical MDS treatment guidelines.&nbsp;Hosted on a web-based, multichannel, open-access platform, the guidelines will be available in a responsive format suitable for phones, tablets, and computers. It’s hoped the mobile responsiveness can be utilized to encourage daily use within clinical practice. We are seeking industry support to ensure this project delivers upon its full potential and generates a comprehensive set of clinically advocated guidelines for use in the frontline hematology setting.&nbsp;Please contact <a href="mailto:sarah.rustin@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">sarah.rustin@scientificeducationsupport.com</a> for further information on how to get involved.&nbsp;&nbsp;<h3><a href="https://know-aml.com/keep-moving-keep-learning" rel="noopener noreferrer" target="_blank">Blood Cancer Awareness Month: “Keep MOVING, Keep LEARNING ”&nbsp;</a></h3>In the sixth year of celebrating Blood Cancer Awareness Month, Know AML will be delivering an education and awareness campaign called “<a href="https://know-aml.com/keep-moving-keep-learning" rel="noopener noreferrer" target="_blank">Keep MOVING, Keep LEARNING.</a>”&nbsp;The campaign aims to:&nbsp;<ul><li>Empower patients by enabling them to have control of their disease journey​.&nbsp;</li><li>Help to improve the patient experience by providing resources to turn to during any stage of the AML journey​.&nbsp;</li><li>Direct patients to sources of information and support in areas such as nutritional support, movement and exercise, complementary therapies, wellbeing and psychological support, management of side effects, and financial and employment assistance.&nbsp;</li></ul>Please support the campaign by:&nbsp;<ul><li>Visiting the <a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(37, 44, 52);">Know AML </a><a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">website</a><a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(37, 44, 52);"> </a>and navigating to the Blood Cancer Awareness Month page and <a href="https://know-aml.com/resources" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">Resources</a><a href="https://know-aml.com/resources" rel="noopener noreferrer" target="_blank" style="color: rgb(37, 44, 52);"> page</a>.&nbsp;</li><li>Sharing the interactive graphic (or PDF version) with anyone who may benefit from it—be that friends, family, colleagues, patients, or caregivers—and help those around you.&nbsp;</li></ul><h2>Supporter update&nbsp;&nbsp;</h2><h3><a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank">Lymphoma Hub&nbsp;</a></h3>We are delighted to confirm that BeiGene will be continuing its support of the Lymphoma Hub. BeiGene’s support is a valued addition to the strong supporter base of chronic lymphocytic leukemia (CLL) stakeholders supporting the platform. Receiving this support is critical for increasing the CLL content on the hub, alongside the plethora of lymphoma content.&nbsp;<h3><a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank">ALL Hub&nbsp;</a></h3>Pfizer will be continuing their support of the ALL Hub at contributor level, which is a huge boost for the platform. Pfizer’s presence in supporting this platform is critical for the future of the education provided to our users. There are exciting plans for Know ALL next year; therefore, we are glad Pfizer have reaffirmed their support for our vision.&nbsp;<h3><a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank">Know ALL&nbsp;</a></h3>We are excited to announce that Know ALL has two new supporters. BMS and Kite Pharma will be supporting the platform in an exciting time for the initiative as we proceed with launching the inaugural World ALL Day and commencing strategic mapping for 2023. We thank these two organizations for showing their support and belief in the necessity of this initiative to provide an international resource in ALL for patients, caregivers, and the general public.&nbsp;<h2>Bespoke educational opportunities&nbsp;</h2>We are seeking grants from our existing and new industry partners to support the delivery of new and innovative educational learning interventions for the hematology community. Through the delivery of these bespoke initiatives across our established learning platforms we hope to demonstrate advanced levels of learning in targeted areas of unmet needs relevant to HCPs.&nbsp;CAR T-cell therapy (a multi-platform webinar series from the Lymphoma Hub, Multiple Myeloma Hub, and ALL Hub &nbsp;In a first for our hematology hubs, this webinar series will address unmet educational needs pertaining to the growing scope of CAR T-cell therapies across the hematology indications. With consideration of the complex treatment journey, from the initial consultation through to transition of care, this project aims to support HCPs involved in this new and evolving treatment area, enabling them to make optimal treatment choices for their patients. Leveraging the remarkable reach of three relevant hub platforms, the content will also remain on the platforms as a valuable source of enduring content.&nbsp;Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis (a clinical trial club)&nbsp;A clinical trials club is a live webinar where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support HCPs in understanding what the latest news means for clinical practice. They offer the ideal solution to address a key learning gap of suboptimal knowledge of novel therapeutic targets in MPN.&nbsp;Sequencing of therapies in acute lymphoblastic leukemia (a case-based symposium)&nbsp;This case-based symposium will discuss the issues associated with the sequencing of therapies for Bcell ALL. A panel of selected ALL key opinion leaders will discuss cases related to this subtype of the disease. Pre- and post-case discussions will help develop the viewers’ understanding of the recommended treatment algorithm in these cases, and viewer interactivity with the panel will help raise confidence and competence in their management of the disease. We are seeking support from industry stakeholders to enable the delivery of this learning initiative.&nbsp;If you would like to learn more about supporting these educational initiatives, please contact the Partnerships Team at <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">partnerships@scientificeducationsupport.com</a>.&nbsp;&nbsp;&nbsp;

Latest partnership activity for Scientific Education Support (SES)

SES Aug22 WebUpdates_0.1_partnerships.png

Partnerships update-August 2022

<a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know ALL</a> is a global education and awareness initiative that provides patients and caregivers with the information, resources, and support they need to deal with acute lymphoblastic leukemia (ALL)—a rare type of leukemia in which the number of white blood cells is not controlled correctly.&nbsp;On September 20, 2022, Know ALL will unite with the ALL community to raise awareness of the disease. We are asking everyone to come together and get involved with our first <a href="https://know-alleukemia.com/get-involved/world-awareness-day" rel="noopener noreferrer" target="_blank">World ALL Day campaign called “my ALL, my story.”</a>More information and details on how to get involved can be found in the <a href="https://know-alleukemia.com/resources" rel="noopener noreferrer" target="_blank">Know ALL resources page.</a>&nbsp;The ALL community can make a difference on World ALL Day and beyond by sharing the World ALL Day resource via social media or any other method. The resource highlights the different ALL subtype classifications and key questions to ask your healthcare provider. The resource is also editable, so patients can share their subtype and personal experience. If you have any questions or would like more information, please do not hesitate to get in touch via our social channels or email.&nbsp;Further information&nbsp;Know ALL has a dedicated and highly experienced global <a href="https://know-alleukemia.com/about-us/who-we-are" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ambassador group</a> who meet regularly to guide the initiative. The ambassador group consists of patients and caregivers, patient advocates, healthcare professionals, and industry representatives. Their role is to propose awareness initiatives, provide concepts for support and education resources, share their experiences and learnings from advocacy heritage, and endorse materials before circulation among the ALL community. Know ALL is brought to you by <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Scientific Education Support (SES)</a> in collaboration with the <a href="https://acuteleuk.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Acute Leukaemia Advocates Network (ALAN).</a>&nbsp;Know ALL owes thanks to its supporters: Amgen, Jazz Pharmaceuticals, BMS, and Kite Pharma.&nbsp;&nbsp;Please <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">contact the partnerships team</a> for more information on how to support this initiative.&nbsp;&nbsp;For more information on Know ALL, please visit <a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">know-alleukemia.com</a> or contact <a href="mailto:ses_knowall@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ses_knowall@scientificeducationsupport.com</a>.&nbsp;&nbsp;Connect with our social channels:&nbsp;&nbsp;Twitter: <a href="https://twitter.com/_KNOW_ALL" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">@_KNOW_ALL</a>&nbsp;&nbsp;Facebook: <a href="https://www.facebook.com/Know-ALL-102633885259544" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know ALL</a>&nbsp;&nbsp;LinkedIn: <a href="https://www.linkedin.com/company/76743323/admin/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know ALL</a>&nbsp;&nbsp;Instagram: <a href="https://www.instagram.com/know.all2021/?hl=en" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">know.all2021</a>&nbsp;

On September 20, 2022, Know ALL will unite with the ALL community to raise awareness of the disease.

SES Aug22 WebUpdates_0.1_ALLday.png

Know ALL is marking the first World ALL Day on September 20, 2022 

This year, we would like to help caregivers and patients better understand AML. During Blood Cancer Awareness Month, we’ll be asking the AML community to come together, support the campaign, and help those who need it most.&nbsp;Our "<a href="https://know-aml.com/keep-moving-keep-learning" rel="noopener noreferrer" target="_blank">Keep MOVING, Keep LEARNING</a>" campaign aims to empower patients by enabling them to have control of their disease journey and improve the patient experience by providing resources to turn to that deliver information and support in areas such as nutritional support, movement and exercise, complementary therapies, wellbeing and psychological support, management of side effects, and financial and employment assistance.&nbsp;&nbsp;You can view our interactive graphic via our <a href="https://know-aml.com/get-involved" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Get Involved page</a> and view our downloadable and editable resources on our <a href="https://know-aml.com/resources?type=blood-cancer-awareness-month&amp;language=English" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Resources page</a>. We encourage you to share the interactive graphic and downloadable resources with anyone who may benefit from them and help those around you—be that friends, family, colleagues, patients, or caregivers.&nbsp;Know AML owes thanks to its supporters—Abbvie,Bristol Myers Squibb, Amgen, Astellas, and Jazz Pharmaceuticals—without whom our work would not be possible.&nbsp;You can support and stay up to date with the campaign by connecting with our social channels.&nbsp;Facebook: <a href="https://www.facebook.com/KNOWAML/" rel="noopener noreferrer" target="_blank" style="color: windowtext;">@KNOWAML</a>&nbsp;Twitter: <a href="https://twitter.com/KNOW_AML" rel="noopener noreferrer" target="_blank" style="color: windowtext;">@KNOW_AML</a>&nbsp;LinkedIn: <a href="https://www.linkedin.com/company/19096351/admin/" rel="noopener noreferrer" target="_blank" style="color: windowtext;">Know AML</a>&nbsp;Instagram: <a href="https://www.instagram.com/knowaml/" rel="noopener noreferrer" target="_blank" style="color: windowtext;">knowaml</a>&nbsp;

Know AML Blood Cancer Awareness Month campaign 2022.

SES Aug22 WebUpdates_0.1_BCAM.png

Know AML Blood Cancer Awareness Month Campaign: Keep MOVING, Keep LEARNING

Medical education is constantly evolving as new research and technologies are developed. To ensure that healthcare professionals are up to date on the latest knowledge and practices, it is essential to conduct regular unmet needs assessments.&nbsp;An unmet needs assessment is a process of identifying the gaps in knowledge and clinical practice among healthcare professionals. This can be done through surveys, interviews, literature reviews, or focus groups. The results can then be used to develop targeted medical education programs that address the specific needs of the target audience.&nbsp;Conducting an unmet needs assessment before developing a medical education program is crucial for several reasons. Firstly, it ensures that medical education programs are relevant and align with the needs of healthcare professionals. Secondly, it can help to identify areas where there is a lack of consensus on best practice. Thirdly, it can help ensure that educational programs effectively improve knowledge and skills.&nbsp;Keeping unmet needs assessments updated ensure that they reflect current real-world practice. This can be done by conducting regular assessments and monitoring the results to identify any changes in the needs of healthcare professionals. For the healthcare professional education platforms run by Scientific Education Support (SES), unmet needs are reviewed at least once a year and any relevant additions are discussed with the hub's steering committee members. By conducting regular reviews of our unmet needs assessments, we ensure that our medical education programs are more effective in addressing the needs of healthcare professionals and improving the quality of care provided to patients.&nbsp;Below are some generic examples of knowledge and clinical practice gaps that could be identified through an unmet needs assessment:&nbsp;<ul><li>Lack of knowledge about the latest treatment options and mechanism of action of novel drug classes&nbsp;</li><li>Lack of knowledge about the side effects of treatment and dose modifications&nbsp;</li><li>Low confidence in making treatment decisions when sequencing therapies&nbsp;</li></ul>To read more about unmet needs assessments, you can find additional resources at <a href="https://www.accme.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">The Association for Continuing Medical Education</a> (ACCME).&nbsp;&nbsp;If you are interested in learning more about our processes when developing an unmet need assessment or information regarding our current needs assessment for our digital platforms, please contact us at partnerships@scientificeducationsupport.com&nbsp;

SES_Jul23_Webupdate_images.png

The Importance of unmet needs assessment in medical education 

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) and Scientific Education Support (SES) are pleased to announce a strategic collaboration for patients with Waldenstrom's macroglobulinemia. The aim is to achieve improved disease awareness and education through initiatives using SES’ expertise in communications and medical education and IWMF’s patient leadership in Waldenstrom's macroglobulinemia.The Waldenstrom’s Macroglobulinemia (WM) Awareness-Building Initiative aims to increase awareness of WM among healthcare professionals, patients, caregivers, and the patient advocacy community. This will be achieved through two key methods:<ul><li>Through the Lymphoma Hub, an independent medical education platform, the initiative will share new data, evidence-based articles, therapy approvals, and expert opinions in WM that support HCPs worldwide by helping them make informed treatment decisions and ensuring that patients have access to the latest support and treatment options.</li><li>Through dedicated patient and caregiver awareness campaigns across social media on IWMF channels, as well as expert interviews and downloadable resources, the initiative will aim to support and educate patients with WM, worldwide.</li></ul>Carl Harrington, Chair of the global WM Awareness-Building Initiative, says “The IWMF is very excited to be working with SES to ensure that all patients with WM and their caregivers never feel they are alone when faced with our rare, incurable but treatable cancer. The mission of the IWMF is to support and educate everyone affected by WM while advancing the search for a cure. We believe this initiative will be critical to accomplishing our mission. Patients with WM, globally, will benefit enormously.”For further information, please contact Barry Connolly at Scientific Education Support:&nbsp;<a href="mailto:barry.connolly@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">barry.connolly@scientificeducationsupport.com</a>About the International Waldenstrom’s Macroglobulinemia Foundation (IWMF)The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-driven, nonprofit organization that is dedicated to supporting and educating everyone affected by Waldenstrom's macroglobulinemia (WM) while advancing the search for a cure.&nbsp;<a href="https://iwmf.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">https://iwmf.com/</a>About Scientific Education Support (SES)SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.Scientific Education Support has a portfolio of successful websites supporting the advancement of medical education in the fields of hemato-oncology, rheumatology, and dermatology:&nbsp;<a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">ALL Hub</a>,&nbsp;<a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">AML Hub</a>,&nbsp;<a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">GvHD Hub</a>,&nbsp;<a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">Lymphoma Hub</a>,&nbsp;<a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">MDS Hub</a>,&nbsp;<a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">MPN Hub</a>,&nbsp;<a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">Multiple Myeloma Hub</a>, and&nbsp;<a href="https://psoriasis-hub.com/" rel="noopener noreferrer" target="_blank" style="background-color: initial; color: rgb(212, 55, 149);">Psoriasis and Psoriatic Arthritis Hub</a>.

Press release to announce The International Waldenstrom's Macroglobulinemia Foundation and Scientific Education Support new strategic collaboration in Waldenstrom's macroglobulinemia

MicrosoftTeams-image (22).png

The International Waldenstrom's Macroglobulinemia Foundation and Scientific Education Support announce new strategic collaboration in Waldenstrom's macroglobulinemia

The Scientific Education Support platforms are carefully crafted to be informed by patients, curated by world leaders in healthcare, and endorsed by expert societies. At the heart of the SES mission lies the commitment to provide healthcare professionals, patients, and carers with solutions that ensure access to independent, impactful, evidence-based information that empowers treatment decisions and increases disease knowledge.&nbsp;The core of our educational hubs and patient platforms is built upon a steadfast commitment to independence and transparency. Every piece of content is developed independently by SES in close collaboration with expert steering committees. This unwavering dedication to independence allows us to uphold the highest standards of credibility and integrity in medical education.&nbsp;So that our IME hubs and patient platforms continue to provide free at source, up-to-date, open-access education, we rely on the invaluable contributions provided by the pharmaceutical industry. Their belief in our mission and dedication to advancing healthcare education has been instrumental in maintaining our continued output of information and education.&nbsp;We would like to acknowledge the companies that have joined recently or continued to support our platforms during 2023.&nbsp;﻿<img src="https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/b0d655126424a0f1c6c406d8cd30545c.png" alt="Black and White Minimalistic Simple Resume.png">

SES Oct23 WebUpdate_supporters.png

Our Valued Partners in Advancing Independent Medical Education

SES is proud to announce that we will be hosting and delivering our first ever webinar series this spring for industry!&nbsp;&nbsp;Topic: The importance of incorporating the patient voice within global IME&nbsp;We are not just experts in creating education for HCPs, but also patient awareness; this puts us in a unique position to bridge the two and bring the patient voice into our HCP education to ensure it is impactful as possible and stands the best chance in making a difference to patients. In addition, our dedicated patient education initiatives empower patients, carers, and families by providing the communication tools to amplify the issues that matter to them.&nbsp;Join us for this 45-minute webinar to explore the importance of incorporating the patient voice at all stages of medical education delivery to ensure that content meets the real-world needs of clinical practice.&nbsp;&nbsp;Sessions will showcase examples from across the SES portfolio to demonstrate the different ways in which we work with patients and patient societies to represent the diverse voices within the community to inform medical education and, ultimately, improve healthcare practice.&nbsp;&nbsp;Objectives&nbsp;&nbsp;Following the meeting, attendees will be able to:&nbsp;<ul><li>Recognize the importance of representing the patient perspective at all stages of medical education provision to deliver efficient, impactful, and practice-changing learning&nbsp;</li><li>Explain how working in close partnership with patient societies drives disease awareness and enhances learning for all&nbsp;</li><li>Identify opportunities for industry stakeholders to support activities that incorporate the patient voice across indications that are aligned with their interests&nbsp;</li></ul>More information will be provided shortly, including a registration page via our social media channels for you to secure your place. In the meantime, if you would like to register your interest in attending, please contact <a href="mailto:partnerships@scietificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">partnerships@scientificeducationsupport.com</a>.&nbsp;Emma WilliamsScientific Education SupportSteering committee season has begun!&nbsp;SES is proud to oversee the content of nine individual IME hubs. Each of these hubs is guided by an international steering committee of world-leading experts in their respective therapy area, who meet regularly to discuss the content and how to support the HCP community. SES and these committees are responsible for creating needs assessments that direct the hubs’ educational objectives each year.&nbsp;SES hosts two steering committee meetings per year to bring together its members to engage in informed conversations on therapies, patient treatment pathways, clinical trials, and more. Content from these meetings can be disseminated on the hubs directly, but it is also used to direct further educational content.&nbsp;&nbsp;Industry plays a big part in the battle against disease; because of this, our steering committee allows supporters of a certain level to attend meetings in an observer capacity. In addition, they receive a report outlining what the committee feels, as a group, is of immediate importance to the HCP and patient communities.&nbsp;The unique relationship that SES has with our steering committee members, in addition to our understanding of the important responsibility that industry has for education and patient outcomes, means we are able to provide significant value to HCPs through the content on our hubs.&nbsp;If you would like to hear more about our steering committees and their meetings, please contact <a href="mailto:partnerships@scietificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">partnerships@scientificeducationsupport.com</a>.Geoff JonesScientific Education SupportCME symposium update: Demystifying the complex&nbsp;The role of ECP in the management of GvHD: Delivering engagement with key targets through live and enduring content&nbsp;In addition to our global IME hubs and patient platforms, SES offer bespoke, CME accredited medical education. Most recently, the GvHD Hub was delighted to host a dedicated symposium addressing the role of extracorporeal photopheresis (ECP) in the management of GvHD, which was expertly chaired by Professor Mohamad Mohty,​ with additional learning delivered by Professor ​Hildegard Greinix​ and Professor ​Daniel Wolff.&nbsp;&nbsp;Sessions recalled the latest data and recommendations relating to ECP use in GvHD. The expert panel provided guidance on how to identify which patients would benefit from ECP and stated factors that may warrant avoidance or deferral of ECP. The symposium also provided guidance on how to combine ECP with other therapies, such as immunosuppressive agents, and shared best-practice recommendations for conducting ECP, including treatment schedules, anticoagulation practice, and safety monitoring strategies.&nbsp;&nbsp;The reach of the live segment of the symposium was diverse, with 300 registrants expanding over 27 countries. This program was accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 2 hours of external CME credit available upon completion.&nbsp;&nbsp;The feedback for the symposium has been fantastic and is a testament to the quality of the education offered. 100% of responders thought the symposium was scientifically valid and that the activity met their expectations. In addition, 100% of respondents committed to use what they had heard in the symposium in their clinical practice.&nbsp;To ensure longevity of the symposium content, the sessions are hosted on the <a href="https://gvhdhub.com/medical-information/key-considerations-for-the-use-of-ecp-in-gvhd" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 0, 0); background-color: rgb(225, 227, 230);">GvHD Hub</a> as three separate videos, with additional written summaries and key visuals from the presentations, as well as the option to download the presentation slides for free. Furthermore, the GvHD Hub contains a designated area for all symposium-related content, including a playlist function that allows viewers of one symposium video to automatically transition to the next. ​&nbsp;&nbsp;Across YouTube and the GvHD Hub, the video content has amassed over 1,000 views in just over 2 months. This highlights a keen interest from our target audience in the content of the symposium. ​Moreover, promotion of the enduring video content was highly successful, achieving almost 4,000 impressions in the same time period. ​&nbsp;This activity was kindly supported by Mallinckrodt Pharmaceuticals through grant funding, but no access to content steering or speaker engagement was provided.&nbsp;As demonstrated, through our educational offerings, SES can provide tailored education that can be designed to specifically address the unmet educational needs and practice gaps most relevant to your specific targets; utilizing a comprehensive needs assessment.&nbsp;&nbsp;For information on how we can assist your organization in the creation and delivery of high-quality independent bespoke medical education at future events, or if you would like to hear more about our hub-based offerings, such as webinars, clinical trial clubs, and symposia, please contact us:Partnerships@scientificeducationsupport.comLucy MurphyScientific Education Support

MicrosoftTeams-image (61).png

Across our portfolio of independent medical education (IME) platforms, Scientific Education Support (SES) is proud to deliver education which is curated by global KOLs, informed by patients, and endorsed by renowned professional societies.&nbsp;&nbsp;Through one such partnership, we have been delighted to benefit from the knowledge and guidance of the European School of Haematology (ESH) across two of our most prominent platforms.&nbsp;&nbsp;First, we worked together in founding and delivering the Multiple Myeloma Hub in 2017. Following the success of this work, their continued curation and collaboration supported the 2021 launch of The ALL Hub.&nbsp;&nbsp;ESH, founded in 1985, is a not-for-profit institution working to disseminate information and learning to promote and facilitate access to state-of-the-art and cutting-edge knowledge in hematology and related disciplines.&nbsp;&nbsp;Currently, ESH believes the most important unmet educational need among hematologists is access to critical discussion and communication with international experts. Like SES, they offer materials to scientists and clinicians free of charge and educate hematologists throughout the world.&nbsp;Our partnership with ESH extends the reach of our platforms to their over 35,000 annual website users; this ensures we can share education to a wider audience.&nbsp;ESH works as part of a tripartite group towards the strategic development of the Multiple Myeloma Hub and ALL Hub, in partnership with SES and the hub steering committees. We are also delighted to have ESH President, Hervé Dombret, as co-chair of the ALL Hub, alongside Charles Mullighan and Franco Locatelli.&nbsp;Also, ESH support and endorse the hub’s activities throughout the year. In partnership with ESH, SES delivers educational activities which aim to enhance knowledge in acute lymphoblastic leukemia and multiple myeloma, through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.&nbsp;We would like to take this opportunity to thank ESH for their ongoing guidance and collaboration, which supports the delivery of medical education for healthcare professionals worldwide.&nbsp;For more information about the Multiple Myeloma Hub or ALL Hub and how you can support education for healthcare professionals, please contact:&nbsp;Partnerships@scientificeducationsupport.com&nbsp;

SES Jul23 Webupdate ESH image.png

Spotlight on professional societies: ESH  

Scientific Education Support (SES) is a medical education provider that builds healthcare professional (HCP) and patient networks that facilitate open access, science-driven, unbiased disease education and awareness through multichannel (digital and social) communications.We are delighted to launch the first SES newsletter and bring updates and insights from our work with HCP and patient audiences. Additionally, we will provide educational updates from thought-leaders in our team and bring you news and the latest data from conferences we attend on behalf of <a href="https://scientificeducationsupport.com/independent-education#education-hubs" rel="noopener noreferrer" target="_blank"> our education hubs</a> .You will also find feature updates from our <a href="https://scientificeducationsupport.com/independent-education#education-hubs" rel="noopener noreferrer" target="_blank"> education hubs</a> and <a href="https://scientificeducationsupport.com/independent-education#patient-programs" rel="noopener noreferrer" target="_blank"> patient programs</a> , including new ways in which you can support them.<h3>Highlights this month:</h3><ul><li><a href="https://scientificeducationsupport.com/updates/what-is-ime-the-values-and-the-rules-for-the-pharmaceutical-industry" rel="noopener noreferrer" target="_blank">An in-depth look at the value of independent medical education</a></li><li><a href="https://scientificeducationsupport.com/updates/the-global-cholangiocarcinoma-alliance-gca-world-cholangiocarcinoma-day-12-february-2022-and-beyond" rel="noopener noreferrer" target="_blank">An update on the recent, successful World GCA Day on behalf of the Global Cholangiocarcinoma Alliance</a></li><li><a href="https://scientificeducationsupport.com/updates/partnerships-update-february-2022" rel="noopener noreferrer" target="_blank">A review from our Partnerships team discussing our upcoming Multiple Myeloma Hub Symposium and Clinical Trials Club, and information on how you can get involved.</a></li></ul>We hope you will find this newsletter a valuable addition to your inbox. Please feel free to share our <a href="https://scientificeducationsupport.com/?newsletter=websiteupdate" rel="noopener noreferrer" target="_blank"> sign-up page</a> with any colleagues you feel would benefit from this new publication.Wishing you all the best on behalf of the SES team.

Scientific Education Support (SES) is a medical education provider that builds healthcare professional (HCP) and patient networks that facilitate open access, science-driven, unbiased disease education and awareness through multichannel (digital and social) communications.

SES Launch Monthly Newsletter

The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration for healthcare professionals (HCPs) in the fields of psoriasis and psoriatic arthritis. The aim of this collaboration is to achieve improved awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.Today, SES has launched the new Psoriasis and Psoriatic Arthritis Hub, with IPC as the founding professional partner. This hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in psoriasis and psoriatic arthritis. The aim of the hub is to enhance knowledge on psoriasis and psoriatic arthritis through the multichannel dissemination of global advances related to classification, diagnosis, treatment, and management.The Psoriasis and Psoriatic Arthritis Hub will share new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.Activity such as this would not be possible without our supporter; therefore, we would like to take this opportunity to welcome UCB and thank them for their support. All hub content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.Speaking at the launch, Mia Hill, IME Director at SES, said:“We are delighted to announce that the Psoriasis and Psoriatic Arthritis Hub is now live. Our vision for the hub is that every treatment team and researcher will have instant access to expert opinions and the latest evidence-based information on psoriasis and psoriatic arthritis to aid in treatment decisions and improve the lives of patients globally.“IPC and SES believe that the Psoriasis and Psoriatic Arthritis Hub will become the solution for time-stretched HCPs to easily access up-to-date medical information to expedite learning and empower their treatment decisions. All hub content is guided by a steering committee of world-renowned experts, informed by patients, and endorsed by expert societies, in order to support HCPs worldwide.”ENDSFor more information on the Psoriasis and Psoriatic Arthritis Hub, please visit&nbsp;<a href="https://psoriasis-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(212, 55, 149); background-color: initial;">https://psoriasis-hub.com/</a>&nbsp;and for more information on the International Psoriasis Council, please visit&nbsp;<a href="https://www.psoriasiscouncil.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(212, 55, 149); background-color: initial;">https://www.psoriasiscouncil.org/</a>.For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.NOTES TO EDITORAbout&nbsp;psoriasisPsoriasis is a chronic immune-mediated skin disease, which commonly manifests as erythematous plaques on the scalp, trunk, buttocks, and extensor aspects of the limbs. Psoriasis can be painful and disfiguring, impacting quality of life. It is also often associated with other autoimmune disorders, cardiovascular disease, and diabetes, impacting healthcare utilization and disease burden.About&nbsp;psoriatic arthritisPsoriatic arthritis, also known as PsA, is an inflammatory joint disease that develops in a significant minority of patients with psoriasis. Psoriatic arthritis is often underdiagnosed and undertreated, with a variable clinical course. Many patients with psoriatic arthritis experience progressive joint disease, impairing physical function and quality of life.About Scientific Education Support (SES)SES is an independent medical education organization that delivers community physician education through therapy hubs, community awareness and education through ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.Over the past decade, SES has conceived, developed, launched, and managed a series of renowned hubs that support the advancement of medical education in the field of hemato-oncology, including the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, MPN Hub, and Multiple Myeloma Hub.About the International Psoriasis Council (IPC)The IPC is a community of physician experts working to improve the health of people with psoriasis around the world. The IPC focuses on helping dermatologists build expertise in psoriasis management and trains physicians to better care for people with psoriasis.

The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration for healthcare professionals (HCPs) in the fields of psoriasis and psoriatic arthritis. The aim of this collaboration is to achieve improved awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases. 

The new Psoriasis and Psoriatic Arthritis Hub is now live

<h2>World ALL Day 2022&nbsp;</h2>On September 20, 2022, the patient and caregiver community united to mark <a href="https://know-alleukemia.com/get-involved/world-awareness-day" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">the first World ALL Day.</a> Focusing on “My ALL, my story,” the inaugural awareness day aimed to highlight three important goals for those living with acute lymphoblastic leukemia (ALL):&nbsp;<ol><li>Explain to the patient and caregiver community why knowledge of ALL subtypes is important for treatment planning​&nbsp;</li><li>Increase knowledge of different ALL subtypes and how they are classified among the community&nbsp;</li><li>Encourage patients to share their subtype and their experience of ALL with others&nbsp;</li></ol>The day was a huge success, and we look forward to seeing it grow year on year. If you would be interested in supporting World ALL Day 2023, please contact our <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Partnerships team.</a>&nbsp;<h2>Blood Cancer Awareness Month 2022&nbsp;</h2>September also saw the return of Blood Cancer Awareness Month, supported by the SES patient initiatives, Know ALL and Know AML. Know AML ran an education and awareness campaign called <a href="https://know-aml.com/keep-moving-keep-learning" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Keep MOVING, keep LEARNING</a>, which aimed to​ empower patients by enabling them to have control of their disease journey​ and help improve the patient experience by providing resources for them to turn to, whatever stage they are at in their AML journey​.&nbsp;There was a large effort to help direct patients to sources of information and support in areas such as nutrition, movement and exercise, complementary therapies, management of side effects, wellbeing and psychological support, and financial and employment assistance.​&nbsp;<h2>64th American Society of Hematology 2022 Annual Meeting and Exposition&nbsp;</h2>The 64th American Society of Hematology (ASH) Annual Meeting and Exposition is arguably the most significant date in the hematology calendar. Our platforms have a fantastic congress coverage facility, and this drives significant traffic to the websites during the period of ASH. HCP engagement with the websites and our social media channels during this critical time is of great value to all industry stakeholders.&nbsp;Our experienced team of medical writers will report on the key data presented at ASH, so we urge our industry stakeholders to engage with our hubs throughout the congress. There are a number of exciting abstracts due to be delivered in New Orleans, and we recommend utilization of the unmet need submission benefit to maximize coverage for our hub communities.&nbsp;&nbsp;Organizations can help raise awareness of key clinical trials—while gaining global recognition among our 300,000 annual visitors—by supporting our platforms, which provide critical, open access education for HCPs across more than 190 countries. If you are interested in finding out more about our plans for ASH, or how you can support our hubs, please don’t hesitate to get in touch with our <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank">Partnerships Team</a>.

The latest activity from the Scientific Education Support partnerships team.

SES Sep22 WebUpdate_0.1_partnerships.png

Partnerships Update-September 2022

SES are delighted to announce that we have been accepted as associate members of the Good CME Practice group!&nbsp;The Good CME Practice group (gCMEp) is a membership organization for European continuing medical education (CME) providers. The mission of the gCMEp is to promote professionalism within the European CME provider community by championing high standards in the development and delivery of CME in Europe, in order to support providers in delivering high quality, independent education for healthcare professionals, with the ultimate aim of improving health outcomes.&nbsp;Following a robust evaluation of our education, SES has been accepted as part of the group, which acknowledges the high quality of the independent education that we deliver and provides a stamp of approval for us as providers of education that is based on true education needs, fair, balanced, transparent, and improves outcomes. We are excited to share this news with our healthcare professional community to provide even more credibility to our offerings and increase the reach of our education. We hope this also provides you, our supporters, with increased trust in our educational offerings and that this strengthens the value of supporting our education for you.&nbsp;&nbsp;If you would like to find out more about the gCMEp, please visit their website here: <a href="https://gcmep.org/about-the-gcmep/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">https://gcmep.org/about-the-gcmep/</a> or do email me with any questions: <a href="mailto:mia.hill@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">mia.hill@scientificeducationsupport.com</a>.&nbsp;&nbsp;Mia Hill&nbsp;Acting Managing Director&nbsp;Scientific Education Support&nbsp;

SES_Jan23_gCMEp_WebUpdate_image.png

SES are now associate members of the Good CME Practice group!

Are you in the thick fog of budget planning for 2023?&nbsp;We want you to consider supporting SES’ independent medical education (IME) platforms in 2023.&nbsp;Here’s why:&nbsp;<ul><li>Year to date, our IME platforms have received over 134,000 unique visitors.&nbsp;&nbsp;</li><li>Based on newsletter statistics, we have seen that over 50% of users are working, frontline hematologists.&nbsp;&nbsp;</li><li>The top 5 countries of access across our platforms include key markets, including United States, United Kingdom, India, Germany, and China (in order of size, largest to smallest).&nbsp;&nbsp;</li><li>Our social media channels are growing, with a total of 1,917,097 Twitter impressions across our 7 IME platforms.&nbsp;&nbsp;</li><li>A total of 123 key opinion leaders make up our steering committees, a number of whom are primary investigators on key pivotal trials within the hematology space. Supporters are able to join a number of the 16 steering committee meetings due to take place across the platforms next year.&nbsp;&nbsp;</li></ul>Our medical writing team will be covering over 26 congresses in 2023, including EBMT, ASCO, EHA, SOHO, and ASH.&nbsp;&nbsp;By utilizing the unmet need submission system, we value the input and ideas of industry stakeholders. You may put forward your suggestions for key educational topics to be reviewed by our steering committee and, if approved, they are disseminated to the community in a variety of formats.&nbsp;&nbsp;&nbsp;If your organization is expecting an important 2023, with key abstracts to be put forward at congresses, expected publications, or the need to deliver key educational messages (e.g., a novel mode of action) into the community, sponsoring our platforms could be a key pillar to your engagement strategy.&nbsp;&nbsp;&nbsp;Should you wish to discuss how we can support your medical educational strategy next year, please contact our Partnerships Team at <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">partnerships@scientificeducationsupport.com</a>.&nbsp;

Latest planning activity for working with Scientific Education Support (SES) 

SES Aug22 WebUpdates_0.1_2023planning.png

Time for budget planning-2023

Based on robust needs assessments to identify the key educational and practice gaps facing each therapy area, the symposia will be designed to address specific learning objectives with a view to improve knowledge and competence among attendees and, ultimately, patient outcomes.

SES Sep22 WebUpdate_0.1_IMEwebinar.png

Upcoming symposia: Spotlighting key topics in multiple myeloma and GvHD 

The SES team is currently planning for several upcoming meetings across our <a href="https://scientificeducationsupport.com/independent-education#education-hubs" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">independent medical education hubs</a> and <a href="https://scientificeducationsupport.com/independent-education#patient-programs" rel="noopener noreferrer" target="_blank">patient programs</a> to facilitate interesting discussions and develop enduring content.&nbsp;&nbsp;Throughout November, we will be hosting steering committee meetings for our hubs. Bringing together world-leading experts in each disease area, our steering committee will meet for the second time in 2022, focusing on an agenda agreed upon by the chair(s).&nbsp;&nbsp;The chair(s) of each hub will facilitate the meetings, firstly giving an update and overview of hub activity and content, including areas of focus, drug updates and developments, and congress coverage. Following the steering committee meetings in April this year, where unmet educational needs were discussed and agreed, the second portion of these meetings will focus on learning objectives, highlighting which have been achieved and how any remaining unmet needs will be met.&nbsp;The next sessions will feature interactive patient case studies, presented by members of the steering committee, as nominated by the chair(s). These sessions will be recorded and developed into content to be housed on the hubs and used as educational resources for our audience of healthcare professionals.&nbsp;Our patient education and awareness initiatives, <a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank">Know AML</a> and <a href="https://know-alleukemia.com/" rel="noopener noreferrer" target="_blank">Know ALL</a>, will both host ambassador meetings this month. Our global ambassador group, including patient advocates, patients, and healthcare professionals, will meet to discuss strategy and activity planning for 2023. Building on this, Know ALL ambassadors will discuss congress and patient interviews, and exciting plans for a Know ALL community meeting. Know AML ambassadors will be focusing on possible themes for AML World Awareness Day in April 2023. In addition, Know AML will be hosting a global network meeting on November 21, inviting our 52 members to take part in expert- and patient-led sessions on participating in a clinical trial with guest speakers.&nbsp;These exciting upcoming meetings are a chance to continue building healthcare professional and patient networks that facilitate open access, science-driven, unbiased disease education and discuss and formulate plans for growth and innovation in 2023. If you would like more information about these meetings or any of our hubs or programs, please see our <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">website</a> or <a href="https://scientificeducationsupport.com/contact-us" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">contact us</a>.&nbsp;

The SES team is currently planning for several upcoming meetings across our independent medical education hubs and patient programs to facilitate interesting discussions and develop enduring content. 

SES Oct22 WebsiteUpdate_0.1_Network.png

Upcoming network meetings 

The Federation of Clinical Immunology Societies (FOCIS) and Scientific Education Support (SES) are thrilled to announce a strategic collaboration for healthcare professionals (HCPs) in the field of lupus. The aim of this collaboration is to achieve improved awareness, knowledge, and understanding of lupus.&nbsp;&nbsp;Today, SES, along with FOCIS, the founding professional partner, has launched the new Lupus Hub. The Lupus Hub is an independent open-access educational website, dedicated to providing balanced, credible, and up-to-date medical education within the lupus space. The aim of the hub is to enhance knowledge on lupus through the multichannel dissemination of global advances related to classification, diagnosis, treatment, and management. To achieve this, the Lupus Hub will share new data, drug updates, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.&nbsp;&nbsp;Speaking at the launch, Betty Diamond, MD, Director of the Institute of Molecular Medicine at the Feinstein Institutes and member of the Lupus Hub Steering Committee, said:&nbsp;&nbsp;“The Lupus Hub will provide up-to-date, evidence-based practice information to healthcare professionals to ensure quality care for patients with lupus. It represents an important new initiative for FOCIS, and an effort to ensure quality care for patients who are at the center of our research activities.”&nbsp;Mia Hill, IME Director at SES, said:&nbsp;“We are excited to announce that the Lupus Hub is now live. Our shared vision with FOCIS is that every treatment team and researcher will have instant access to expert opinions and the latest evidence-based information on lupus to aid in treatment decisions and improve the lives of patients globally.&nbsp;“FOCIS and SES believe that the Lupus Hub will become the solution for time-stretched HCPs to easily access up-to-date medical information to expedite learning and empower their treatment decisions. All hub content is guided by a steering committee of world-renowned experts, informed by patients, and endorsed by expert societies, in order to support HCPs worldwide.&nbsp;“Activity such as this would not be possible without our supporters, GSK and AstraZeneca; therefore, we would like to take this opportunity to welcome GSK and AstraZeneca and thank them for their support. We welcome interest from all supporters that are keen to understand more about the Lupus Hub and how they can contribute to enhancing knowledge of lupus for HCPs around the world.”&nbsp;ENDS&nbsp;All hub content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.&nbsp;For more information on the Lupus Hub, please visit <a href="http://www.lupushub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">www.lupushub.com</a>, and for more information on FOCIS, please visit <a href="http://www.focisnet.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">http://www.focisnet.org</a>.&nbsp;For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.&nbsp;&nbsp;NOTES TO EDITOR&nbsp;About lupus&nbsp;Systemic lupus erythematosus (SLE), commonly referred to as lupus, is a complex autoimmune disease commonly affecting the skin, joints/muscles, kidneys, and blood vessels. SLE is characterized by a relapsing remitting disease course, organ damage, and highly variable manifestations, which often overlap with other conditions, such as rheumatoid diseases, hematopoietic malignancies, and infections, which can lead to delayed diagnosis.&nbsp;A common complication of SLE is lupus nephritis (LN), where the immune system targets the kidneys. LN significantly impacts morbidity and mortality and can result in chronic kidney disease and kidney failure. LN is also associated with cardiovascular morbidity and mortality, as well as adverse fertility and pregnancy outcomes.&nbsp;Early diagnosis and effective treatment are vital to achieve sustained immunologic responses and improved outcomes for patients with SLE and LN.&nbsp;&nbsp;About Scientific Education Support (SES)&nbsp;SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.&nbsp;Scientific Education Support has a portfolio of successful websites supporting the advancement of medical education in the fields of hemato-oncology, rheumatology, and dermatology: <a href="https://lymphoblastic-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ALL Hub</a>, <a href="https://aml-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">AML Hub</a>, <a href="https://gvhdhub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">GvHD Hub</a>, <a href="https://lymphomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lymphoma Hub</a>, <a href="https://mds-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MDS Hub</a>, <a href="https://mpn-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">MPN Hub</a>, <a href="https://multiplemyelomahub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Multiple Myeloma Hub</a>, and <a href="https://psoriasis-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Psoriasis and Psoriatic Arthritis Hub</a>.&nbsp;&nbsp;About the Federation of Clinical Immunology Societies (FOCIS)&nbsp;FOCIS exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases. FOCIS is a key forum where opinion leaders come together to chart the path to the next major breakthrough in disease therapy.&nbsp;Through FOCIS, researchers and clinicians share knowledge across traditional disease borders, and identify commonalities between treatments and therapies that are life-changing for those impacted by immune-mediated diseases. <a href="https://www.focisnet.org/education/advanced-course-in-basic-clinical-immunology/" rel="noopener noreferrer" target="_blank" style="background-color: rgb(225, 227, 230); color: rgb(0, 0, 0);">Visit the website for more information</a>.&nbsp;&nbsp;

SES Oct22 WebsiteUpdate_0.1_Lupus.png

The new Lupus Hub is now live 

October saw the SES team celebrate the launch of the <a href="https://lupushub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Lupus Hub</a>, supported by AstraZeneca and GSK.&nbsp;The Lupus Hub, alongside the <a href="https://psoriasis-hub.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Psoriasis and Psoriatic Arthritis Hub</a>, form SES’ independent medical education platforms within immunology. The Lupus Hub officially launched with the coverage of the 13th European Lupus Meeting in Stockholm, Sweden, on October 5, 2022, where our medical writing team on the ground delivered fantastic <a href="https://lupushub.com/congresses/sleuro/sleuro-2022" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">coverage</a>.&nbsp;After a successful launch period, we are delighted to highlight an overview of the engagement achieved within the immunology community:&nbsp;<ul><li>The Lupus Hub’s tweets during the first week of launch achieved an engagement rate of 6.5% and earned 5,000 impressions, amounting to over 900 a day on average. Achieving these metrics so early in the delivery of the hub reflects the quality and relevance of the content currently produced by the team.&nbsp;</li><li>During the 13th European Lupus Meeting, the Lupus Hub achieved status within the top ten most prolific tweeters during the event.&nbsp;</li><li>The popularity of the Lupus Hub Twitter channel had been highlighted by the engagement received from 4/5 of the top influencers within the Systemic lupus erythematosus network on Twitter.&nbsp;</li><li>Through the support of our multi-disciplinary steering committee, consisting of both clinical key opinion leaders and patient advocates, the platform consistently secured high engagement with the top ten influencers for the Lupus2022 hashtag.&nbsp;</li></ul>If you are interested in supporting us to further the reach of the valuable education that the Lupus Hub provides to the immunology community, please get in touch with our <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Partnerships team</a>.&nbsp;<h2>MDS International Guidelines&nbsp;</h2>The MDS International Guidelines is a project developed with the mission of raising the global standards of disease management in MDS through the development of contemporary and practical MDS treatment guidelines.&nbsp;Hosted on a web-based, multi-channel platform with open access to users, the guidelines will be available in a responsive format suitable for phones, tablets, and computers. We hope to utilize mobile responsiveness to encourage daily use within clinical practice. We are seeking industry support to ensure that this project delivers its full potential and generates a comprehensive set of clinically advocated guidelines for use in the frontline hematology setting. Please contact <a href="mailto:ken.zangina@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">ken.zangina@scientificeducationsupport.com</a> for further information.&nbsp;<h2>Supporter update&nbsp;</h2>Lupus Hub&nbsp;We are delighted to welcome AstraZeneca as a supporter of the new Lupus Hub. The Lupus Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Joining GSK as a Platinum supporter, we look forward to seeing the collaboration with AstraZeneca grow along with the footprint of this exciting platform.&nbsp;AML Hub&nbsp;The AML Hub welcomes a new Bronze supporter—Kronos Bio. Kronos Bio’s support is a valued addition to the strong supporter network of AML stakeholders currently supporting the platform. The growing importance of measurable residual disease (MRD), both in diagnosis and treatment monitoring, reflects the support needed from organizations such as Kronos Bio, who are innovators in utilizing MRD as an endpoint within their clinical trial.&nbsp;MPN Hub&nbsp;Bristol Myers Squibb will be continuing their support of the MPN Hub as a Gold level supporter in a resounding show of support to our commitment to medical education in MPN. As a critical industry stakeholder in MPN, we are pleased to develop the collaboration between the platform and the team at Bristol Myers Squibb.&nbsp;<h2>Bespoke educational opportunities&nbsp;</h2>We are seeking grants from our existing and new industry partners to support the delivery of new and innovative educational learning interventions for the hematology community. Through the delivery of these bespoke initiatives across our established learning platforms, we hope to demonstrate advanced levels of learning in targeted areas of unmet needs relevant to healthcare professionals.&nbsp;CAR T-cell therapy – Cross-platform webinar series (Lymphoma, Multiple Myeloma, and ALL Hubs)&nbsp;In a first for the hematology hubs, this series of webinars will address unmet educational needs pertaining to the growing scope of CAR T-cell therapies across the hematology indications. With consideration of the complex treatment journey from the initial consultation through to transition of care, this project aims to support healthcare professionals involved in this new and evolving treatment area, enabling them to make optimal treatment choices for their patients. Leveraging the remarkable reach of three relevant hub platforms, the content will also remain on the platforms as a valuable source of enduring content.&nbsp;Please contact the Partnerships team on <a href="mailto:partnerships@scientificeducationsupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">partnerships@scientificeducationsupport.com</a> if you would like to learn more about supporting these educational initiatives.&nbsp;

The latest updates from the SES partnerships team (October 2022) 

Business Development Update-October 2022

SES Oct22 WebsiteUpdate_0.1_MDS.png

MDS International Guidelines: SES working alongside key individuals and organizations to improve the quality of care for patients with MDS 

Beth Mitchell (Senior Project Director) and Claire Aukim-Hastie (Scientific Services Director) recently had the pleasure of attending the <a href="https://www.cmeforum.org/Default.aspx?gclid=CjwKCAiApvebBhAvEiwAe7mHSAUTM9-c0WFt7LXwJGxNKlbyiWlVvr3V5rIL6IM255-U1l9aYgQZwhoCW7sQAvD_BwE" rel="noopener noreferrer" target="_blank">15th Annual European CME Forum</a> in Barcelona, ES. This was a jam-packed 3-day event, with the theme of reevaluating European and global CME-CPD.&nbsp;Day 1 kicked off with sessions focused on innovation and impact, as well as interactive workshops about how to incorporate the patient voice into education for healthcare professionals. This session walked the group through design thinking and the importance of working with patients as educators in programs from the initial conception.&nbsp;Through a mixture of plenary sessions, panel debates, and workshops, Day 2 discussed the culture of learning and finding the “magic middle” when designing and delivering educations. Some top tips from grantors on applications to supporters were also provided. It was exciting to see our Lupus Hub Chair, Ricard Cervera in attendance.&nbsp;The final day wrapped up the informative meeting with discussions about CME around the world and how as a community we can collaborate together to reach our destination.&nbsp;Discussing the event, Beth Mitchell, Senior Project Director at SES, said:&nbsp;“I thoroughly enjoyed attending the CME Forum; the sessions were very informative and engaging. It was a fantastic opportunity to network with like-minded organizations and meet people in person! I feel excited about putting all the learnings into action and look forward to utilizing all the great resources to build on our educational programs.”&nbsp;

SES attended the 15th Annual European CME Forum 

The Know AML team hosted a Global Network Meeting on Monday, November 21, bringing together patient advocates, patients, and healthcare professionals to discuss the important topic of clinical trials within acute myeloid leukemia.&nbsp;&nbsp;This 90-minute educational meeting designed to support knowledge increase among <a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know AML</a> members and the wider community featured two guest speakers, who both gave sessions on participating in clinical trials, but from different perspectives.&nbsp;&nbsp;The expert-led session hosted by Dr Karen-Sue Carlson, Medical College of Wisconsin, Milwaukee, US, covered the question of “What is it like to participate in a clinical trial?” Dr Carlson presented an overview of what clinical trials are and why they are important, before moving on to outline what is involved in participating in a clinical trial. Dr Carlson approached the important topic of what patients should consider when deciding to participate in a clinical trial and also provided information on where patients and caregivers can find out more information about clinical trials, including location and eligibility. The final section of Dr Carlson’s session focused on how clinical trials can help to improve patient care and how organizations can collaborate to support this.&nbsp;&nbsp;The second session was patient-led by Ralph Hills, who focused on the “Experience of participating in a clinical trial​.” Ralph presented his own journey with acute myeloid leukemia, including the diagnosis, initial prognosis, and treatment options, and how and where Ralph found out about the clinical trial he ultimately took part in. He spoke about the options that were available to him and the decision-making throughout the journey for Ralph, his wife and main caregiver, Dorcas, and their family. Ralph also gave an insight into his life since the clinical trial, including some of the people who have heard Ralph’s story and when Ralph received his first standing ovation!&nbsp;&nbsp;Following the sessions, we had positive feedback from attendees, and we are currently working on developing the recordings into enduring educational content to be housed on the <a href="https://know-aml.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">Know AML website</a>.&nbsp;&nbsp;These meetings are a chance to continue building healthcare professional and patient networks that facilitate open access, science-driven, unbiased disease education, and awareness. If you would like more information about these meetings or any of our programs, please see our <a href="https://scientificeducationsupport.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">website</a> or <a href="https://scientificeducationsupport.com/contact-us" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">contact us</a>.&nbsp;

The Know AML team hosted a Global Network Meeting on Monday, November 21, bringing together patient advocates, patients, and healthcare professionals to discuss the important topic of clinical trials within acute myeloid leukemia.  

SES Nov22 Web update image_KnowAML.png

Know AML Global Network Meeting 

<h2>Introducing our new Senior Partnerships Manager, Lucy Murphy&nbsp;</h2>Lucy has over 10 years’ experience in partnership development across medical education, social policy, and public health. Most recently, she was a Development Manager at WLZ, a social impact bond-funded early intervention program for children and young people addressing the attainment gap for disadvantaged youth struggling with their social, emotional, and academic wellbeing, targeting communities of high deprivation in London.&nbsp;Prior to this, Lucy was at the Royal College of Physicians (RCP), working to align cross-specialty CME, delivered on-site and through their online medical education hub, for clinicians of all career stages. Before RCP, she spent 4 years with the National Cancer Research Institute (NCRI) developing the commercial offering through sponsorship opportunities at the annual congress, and before this, Lucy was the Sponsorship Manager at the Royal Society of Medicine (RSM) for 6 years working across 59 medical specialty sections to identify opportunities and secure funding of academic events for healthcare professionals.&nbsp;Lucy is looking forward to joining the brilliant SES team as a Senior Partnerships Manager to support industry engagement across the independent medical education hubs and patient networks through development of strong relationships.&nbsp;<h2>CME symposia update&nbsp;</h2><h3>Multiple Myeloma Hub: Holistic pain management in multiple myeloma&nbsp;</h3>On November 10, 2022, the Multiple Myeloma Hub hosted an EBAC accredited symposium on holistic pain management in multiple myeloma, which was worth 1 CME credit for live attendees.&nbsp;Chair Professor Mohamad Mohty was joined by expert speakers Professor Heinz Ludwig (Wilhelminen Cancer Research Institute, Vienna, AT), Dr Barry Quinn (Queens University Belfast, Belfast, IE), and Professor Flaminia Coluzzi (Sapienza University of Rome, Rome, IT).&nbsp;The speakers covered a range of topics, with Professor Heinz sharing insight on the presentation and management of pain in early stages of multiple myeloma, the importance of patient-reported outcomes to assist HCPs with accurately assessing pain, and an individualized holistic pain management plan. Dr Quinn spoke on the implementation of a holistic pain treatment plan in advanced disease, including barriers to pain assessment and communication, patient perspectives such as hidden pain, and how to overcome barriers to holistic pain assessment. Finally, Professor Coluzzi delivered a detailed and practical session on “dos” and “don’ts” in pain management, exploring challenging elements of pain management, such as prescribing with comorbidities (e.g., hepatic impairment), the use of rapid-acting opioids, and managing opioid side effects.&nbsp;Videos from the symposium will soon be added to the Multiple Myeloma Hub as enduring content, with updates shared via the hub’s social channels and homepage.&nbsp;<h3>GvHD Hub: The role of ECP in the management of GvHD&nbsp;</h3>On November 29, 2022, the GvHD Hub hosted a further EBAC accredited symposium on the role of extracorporeal photopheresis (ECP) in the management of graft-versus-host disease (GvHD), which was worth 2 CME credits for live attendees and was also chaired by Professor Mohamad Mohty. The symposium provided an opportunity for participants to interact with a world-renowned faculty and hear expert recommendations on treating patients with GvHD using ECP.&nbsp;Sessions from key opinion leaders, Professor Hildegard Greinix and Professor Daniel Wolff, explored patient selection, best practice recommendations, and combination treatments with ECP. The panel also led an interactive case-based discussion around the key considerations for the use of ECP plus steroids in GvHD.&nbsp;Video content from the symposium will soon be added to the GvHD Hub as enduring content, with updates also shared via the hub’s social channels and homepage.&nbsp;<h2>SES at the 64th ASH Annual Meeting and Exposition&nbsp;</h2>The SES team will be in New Orleans for the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on December 10–13, 2022.&nbsp;We look forward to connecting with our industry partners and contacts and providing some fantastic updates from all of SES’ hematology platforms, particularly regarding the latest 2022 engagement statistics.&nbsp;Visit us at Booth 301 to learn about how we are driving quality open access, science-driven disease education through multichannel communications.&nbsp;&nbsp;Please also contact the partnerships team at <a href="mailto:partnerships@scientifceducationshupport.com" rel="noopener noreferrer" target="_blank" style="color: rgb(5, 99, 193);">partnerships@scientifceducationshupport.com</a> should you wish to meet with the team at this event.&nbsp;<h2>Supporter update&nbsp;&nbsp;</h2>AML Hub&nbsp;The AML Hub welcomes a new supporter, Astellas, who will be supporting the platform at a contributor level. Astellas is a well-valued addition to the strong supporter base of the AML Hub. The AML Hub also thanks BMS for renewing their support as a bronze supporter. BMS are a key contributor to the AML treatment pathway and we are delighted to see their reaffirmation of support for the AML Hub.&nbsp;Multiple Myeloma Hub&nbsp;BMS will be continuing to support the Multiple Myeloma Hub as a silver level supporter, which is a resounding show of support to our commitment to medical education in multiple myeloma. As a critical industry stakeholder in multiple myeloma, we are pleased to further develop our partnership with the BMS team.&nbsp;

Overview of partnerships activity for Scientific Education Support

Partnerships Update: November 2022 

Our educational programs are based on robust needs assessments, constructed to identify the key education and practice gaps evident within a therapy area. 

SES Nov22 Web update image_Quiz.png

SES Hubs: Improving outcomes in hematology  

<h3>Thank you to our supporters – Mia Hill&nbsp;</h3>As the year comes to a close, I would like to take the opportunity to reflect on all the hard work that has been carried out by our organization and everything that we have achieved throughout the year.&nbsp;We are proud of the fact that our education solutions have enhanced knowledge among healthcare professionals (HCPs) by improving access to balanced, credible, and up-to-date medical education where there is an unmet need. Our Patient Advocacy Team have also ensured that the patient voice is represented throughout our work and improving patient outcomes will always be at the forefront of our educational work.&nbsp;With the launch of two new hubs (Lupus Hub and Psoriasis and Psoriatic Arthritis Hub) and hosting three CME accredited online events, we have reached new audiences and enhanced our offering to time-stretched HCPs. We also launched our new patient program, Know ALL, which is a global education and awareness initiative that provides patients and caregivers with the information, resources, and support they need to deal with acute lymphoblastic leukemia.&nbsp;&nbsp;As our educational content and engagement with our outcome assessments grow across our hubs, we anticipate seeing a strengthening impact on outcomes. Importantly, our outcomes feed back into our needs assessment process, ensuring we are continually optimizing our education. This approach guarantees we are consistently providing effective education, in areas where it is needed, to improve patient outcomes.&nbsp;Working alongside our Scientific Services Team and Education Lead, our Digital Team have continued to develop and implement innovative improvements to our hubs, such as learning objectives for content, outcomes assessment (a pre‑and post‑content quiz to assess knowledge change), Google Translate (providing hub content in &gt;100 languages), and live drug updates (a notice board for the latest updates in treatment options). We also have some exciting updates for 2023, including educational resource centers (a dedicated learning space for users to learn and test their knowledge), podcast libraries (one central location for the latest and historical hub podcasts), user accounts (personalized content and landing pages for all hub users), and increased accessibility (audio narration for all articles on our hubs).&nbsp;&nbsp;It has also been so exciting to see our Partnerships Team and medical writers travel across the globe to meet with our supporters and engage with esteemed opinion leaders at key congresses. Most recently, the SES team were in New Orleans for the 64th American Society of Hematology (ASH) Annual Meeting and Exposition; it was fantastic to connect with our industry partners and provide them with some excellent updates from our hematology platforms, particularly regarding the latest 2022 engagement statistics.&nbsp;These and so many other successes were achieved during a difficult time, which is why I’d like to also pay tribute to the team at SES, our steering committee members, partners, supporters, and friends, who make what we do so rewarding and impactful in several communities. The dedication and commitment of our team has been exceptional throughout the year and all efforts are very much appreciated.&nbsp;Finally, I would like to wish you and your family peace, prosperity, and good health throughout 2023. We can’t do what we do without our supporters and SES remain committed to making a difference through education.&nbsp;We look forward to sharing further exciting updates with you in the new year.&nbsp;Kind Regards,&nbsp;Mia Hill&nbsp;Acting Managing Director&nbsp;Scientific Education Support&nbsp;

Meet the SES Partnerships Team at EHA2023

Sign Up For Our Monthly Newsletter